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Abstract 
Pituitary adenomas are common intracranial neoplasms that generally arise sporadically. However, a 
small minority occurs in a familial setting, often as aggressive and difficult-to-treat adenomas in 
patients who are relatively young. Familial syndromes with phenotypes including pituitary adenomas 
include multiple endocrine neoplasia type 1 (MEN1), Carney complex and MEN4. Recently, a fourth 
gene underlying pituitary adenomas was discovered in Northern Finland in a cluster of familial 
acromegaly. Heterozygous mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene 
caused this condition, designated as pituitary adenoma predisposition (PAP). PAP confers incomplete 
penetrance of pituitary adenomas, and patients often lack a strong familial background of adenomas. 
AIP mutation positive (AIPmut+) patients are often young at disease onset and have mostly growth 
hormone (GH) secreting adenomas. Loss of heterozygosity of AIP in tumors and functional evidence 
suggest that AIP is a tumor suppressor gene.  
Elucidation of the molecular mechanisms of PAP is a requirement for better understanding of the 
detailed genesis of these pituitary adenomas. Moreover, clarification of the clinical characteristics of 
PAP may be beneficial in establishing genetic testing protocols to recognize individuals at risk for 
developing tumors and to improve patients’ clinical outcome. Development of novel treatment 
regimes relies on detailed knowledge of tumorigenesis. This thesis work aims to clarify the molecular 
and clinical characteristics of PAP.  
 
Applying the multiplex ligation-dependent probe amplification (MLPA) assay, we searched for large 
genomic AIP deletions in apparently AIP mutation negative (AIPmut-) familial pituitary adenoma 
patients. For the first time, genomic AIP deletions were found in two families, suggesting that this 
mutation type accounts  for  a  subset  of  PAP. Therefore,  MLPA could be considered in cases with a  
phenotype indicative of PAP but when no AIP mutations are found with conventional sequencing. 
 
To clarify molecular mechanisms of AIP-mediated tumorigenesis, we elucidated the expression of 
AIP-related molecules in AIPmut+ and AIPmut- pituitary tumors. The expression of aryl hydrocarbon 
receptor nuclear translocator (ARNT) protein was reduced in AIPmut+ pituitary adenomas, whereas 
the nuclear expression of aryl hydrocarbon receptor (AHR) was somewhat increased. This result was 
endorsed by underexpression of ARNT in an Aip knockdown rat mammosomatotroph cell line. These 
results suggest that ARNT, AHR or both may play a role in AIP-related tumorigenesis, possibly via 
pathways involving phosphodiesterases and cyclic adenosine monophosphate. 
 
We generated an Aip mouse model to examine pituitary tumorigenesis in vivo. Heterozygous Aip 
mutations conferred complete penetrance of pituitary adenomas in these mice, and the vast majority of 
adenomas were GH-secreting. Thus, the tumor phenotype of the Aip mouse is similar to that in human 
PAP patients. As in the study on human tumors, aberrant ARNT, but also ARNT2 expression, was 
evident in mouse pituitary adenomas that were Aip-deficient. Our results suggest that AIP may 
function as a candidate gatekeeper gene in somatotrophs. Furthermore, this disease model is an 
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excellent tool in further elucidation of the molecular mechanisms of pituitary tumorigenesis, and it 
also has potential in developing therapeutic approaches.  
 
We studied the clinical characteristics and the response to therapy of AIPmut+ pituitary adenoma 
patients, with sporadic acromegaly patients as a control population. AIPmut+ adenomas conferred an 
aggressive disease phenotype with young age at disease onset. AIPmut+ adenomas were most often 
large, expansive and invasive at diagnosis. Patients were predominantly male, and GH-secreting 
adenomas appeared in nearly 80%. AIPmut+ adenomas also seemed to have many difficult-to-treat 
clinical characteristics. The aggressive nature of AIPmut+ adenomas is further supported by increased 
expression of the Ki-67 proliferation marker in mouse pituitary adenomas that are Aip-deficient. We 
conclude that the improvement in treatment outcomes for PAP patients would require efficient 
identification of AIPmut+ patients, as well as earlier diagnosis of the pituitary adenomas. 
 
The possible role of the rearranged during transfection (RET) proto-oncogene in tumorigenesis of 
familial AIPmut- pituitary adenomas was evaluated. Five novel germline heterozygous RET variants 
were found in the patients; however, none of these could be considered causative of pituitary 
tumorigenesis. Surprisingly, RET immunohistochemistry suggested possible underexpression of RET 
in AIPmut+ pituitary adenomas – an observation that merits further investigation. 
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Review of the Literature 
1. The genome and tumorigenesis 
The human body is composed of approximately 3 x 1013 cells, nearly all of which contain the same 
genetic material. This material resides in the nucleus as chromosomes that contain the 
deoxyribonucleic acid (DNA) sequence, which encodes the ~22 000 genes of the genome. In addition, 
a small fraction of DNA is contained within the mitochondria. Genes encoded by the DNA sequence 
constitute the templates for amino acid (aa) sequences of proteins that carry out the genes’ purposes in 
the cells; the genotype creates the phenotype of an individual through proteins. Gene expression is 
stringently regulated in time and space. An important example of this is the regulation of the 
expression of genes involved in cell division of somatic cells. Proper tissue architecture is maintained 
by appropriate proportions of constituent cell types, replacement of missing cells and discarding of 
unneeded cells. This process of normal growth involves a delicate balance between growth factors and 
growth-inhibitory factors in the surroundings of cells (Weinberg 2007 p.9, 19, 43, 121).  
Deviations from normal growth can involve hyperplasia, designating an excessive numbers of cells; 
metaplasia, when certain cells are displaced by cells of another type that are normally not encountered 
in that site; dysplasia, when cells have reached a cytologically abnormal stage; and ultimately 
neoplastic and metastatic lesions. The genesis of tumors results from the abnormal proliferation of 
normal cells, which is accompanied by the accumulation of genetic defects in these cells (Weinberg 
2007 p.36-39, 43). A succession of genetic changes confers a growth advantage, leading to the 
progressive conversion of normal cells into cancer cells (Hanahan & Weinberg 2000). Since the 
karyotypes of cancer cells are usually abnormal, cancer can be seen as a genetic disease of somatic 
cells (Knudson 2002). Recent evidence suggests that cancers of distinct subtypes within an organ may 
be derived from different ‘cells of origin’, and that these are the cells that acquire the genetic changes 
that culminate in the initiation of cancer (Levy 2008, Vankelecom 2011, Visvader 2011).   
Tumors are initiated by the first genetic alteration that renders a fitness advantage to a cell, and tumor 
progression is the multi-step evolution of a normal cell into a tumor cell (Weinberg 2007 p.G20, 
Bozic et al. 2010). The mutations that are essential in the initiation of tumorigenesis are known as 
“drivers” and they confer a growth advantage, causing the positive selection of the cell in which they 
occur. However, the majority of somatic mutations are “passengers”, which are expected to be 
biologically neutral since they do not confer a growth advantage to the cell in which they occur and 
they are not causative of oncogenesis (Greenman et al. 2007). It has been reported that, for example, 
in typical breast and colorectal cancers there are ~80 aa-altering mutations in the tumor DNA and that 
~15 of these mutations are likely to be responsible for driving initiation, progression or maintenance 
of the tumor (Wood et al. 2007). 
 
It has been postulated that cancer cells comprise six essential alterations in cell physiology that define 
their malignant growth. These are self-sufficiency in growth signals, insensitivity to growth-inhibitory 
(antigrowth) signals, evasion of programmed cell death (apoptosis), a limitless replicative potential of 
cells, sustained angiogenesis, and tissue invasion and metastasis (Hanahan & Weinberg 2000). Also 
genomic instability, for example resulting from mutations in DNA repair genes, has recently been 
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suggested to be a hallmark of cancer (Negrini et al. 2010, Hanahan & Weinberg 2011). Emerging 
views also suggest that the genetic changes in cancer cells are not sufficient and that tumor 
progression is dependent on ancillary processes provided by the tumor environment but not 
necessarily cancerous themselves, such as inflammation and a shift in cellular metabolism (Rakoff-
Nahoum 2006, Tennant et al. 2009, Hanahan & Weinberg 2011).  
 
In contrast to malignant cancer, benign tumors are by definition confined to a specific site of a tissue 
and give no evidence of invading adjacent tissues (Weinberg 2007 p.G2). They are composed of well-
differentiated cells that closely resemble their normal counterparts, and their rate of growth is usually 
slow (Kumar et al. 2003 p.168-173). However, benign tumors can cause significant morbidity and 
even mortality, for example pituitary adenomas can do so by compressing critical brain structures 
(Elston et al. 2009). 
1.1 Oncogenes 
Tumor cells can exhibit abnormal activation of certain normal genes to promote tumorigenesis. These 
genes are called oncogenes and one mutated allele of such a gene is sufficient to confer a selective 
growth advantage to the cell. Oncogene activation can be caused by chromosomal translocations, gene 
amplifications or intragenic mutations affecting crucial residues that regulate the activity of the gene 
product (Vogelstein & Kinzler 2004). Translocations and intragenic mutations can occur either as 
initiating effects of tumorigenesis or during tumor progression, whereas gene amplification usually 
occurs during tumor progression (Croce 2008). Oncogenes encode proteins that can control cell 
proliferation, apoptosis or both. The products of these oncogenes can be classified into six groups of 
molecules: transcription factors, chromatin remodelers, growth factors, growth factor receptors, signal 
transducers and apoptosis regulators. Known oncogenes of the six classes include v-myc (transcription 
factor), ALL1 (chromatin remodeler), KS3 (growth factor), rearranged during transfection (RET) 
proto-oncogene (growth factor receptor), K-RAS (signal transducer) and BCL2 (apoptosis regulator) 
(Croce 2008, Table 1). 
Table 1. Oncogenes and tumor suppressor genes, data from Bronner et al. 1994, Kinzler & Vogelstein 
1998, Soussi 2000, Weber et al. 2006 and Croce 2008. 
Gene Mechanism in tumorigenesis 
Oncogene Activating mechanism 
v-myc  deregulated activity of transcription factor 
ALL1  chromatin remodelling 
KS3 constitutive production of growth factor  
RET constitutive action of growth factor receptor 
K-RAS  signal transduction 
BCL2  inhibition of apoptosis  
Tumor suppressor gene Inactivating mechanism 
p53  evading apoptosis (gatekeeper) 
RB1 uncontrolled proliferation (gatekeeper) 
MLH1  genome instability (caretaker) 
BRCA1  genome instability (caretaker) 
POLD1 generating unstable stroma (landscaper) 
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1.2 Tumor suppressor genes 
Tumor suppressor genes are antigrowth genes whose involvement in tumor formation occurs when 
these genes are inactivated or lost (Weinberg 2007 p.209-210). A model for tumor suppressor gene 
associated cancer development was proposed in 1971, when Alfred Knudson published his “two-hit” 
hypothesis based on epidemiological studies on retinoblastoma patients. He suggested that a 
mutational event must occur in both alleles of a tumor suppressor gene for the affected cell to acquire 
a growth advantage (Knudson 1971).  
Mutations in tumor suppressor genes have the opposite effect to oncogene mutations, since they 
reduce the activity of the gene product. Such inactivation can arise from amino acid changes at 
residues that are essential for the activity of the gene product, from mutations that result in a truncated 
protein, from gene deletions or insertions, or from epigenetic silencing (Vogelstein & Kinzler 2004). 
Interestingly, some tumor suppressor genes exert a selective advantage on the cell even when only 
one allele is inactivated and the other remains functional, a situation that is called haploinsufficiency 
(Santarosa & Ashworth 2004). However, inactivation of both alleles of a tumor suppressor gene is 
generally required to confer a selective advantage to the cell. This situation often arises through an 
intragenic mutation in one allele, coupled with a deletion of the other allele via a gross chromosomal 
event (Knudson 2002). Generally, this phenomenon where the second allele is lost is called loss of 
heterozygosity (LOH) (Weinberg 2007 p.219-224). 
 
Tumor suppressor genes can have functions over the control of cellular proliferation directly acting as 
“gatekeepers”, or they can function in maintaining the integrity of the genome as “caretakers”. 
Inactivation of a caretaker gene does not promote tumor initiation directly, but does so indirectly by 
leading to genetic instability which results in increased mutation rates of all genes including 
gatekeepers (Kinzler & Vogelstein 1997). Classical tumor suppressor genes from these groups include 
p53 (gatekeeper), MLH1 (caretaker) and breast and ovarian cancer 1 and 2 (BRCA1 and BRCA2) 
(caretakers) (Bronner et al. 1994, Kinzler & Vogelstein 1998, Soussi 2000, Table 1). Interestingly, 
some mutant forms of p53 can  also  act  as  oncogenes  (Harris  &  Hollstein  1993).  A  third  group  of  
tumor suppressor genes are the “landscapers”. It is postulated that alterations in landscaper genes can 
cause proliferation of stromal cells. This genetically unstable stroma results in an abnormal 
microenvironment that may promote neoplastic transformation of associated epithelial cells (Kinzler 
& Vogelstein 1997, Kinzler & Vogelstein 1998, Weber et al. 2006, Table 1).  
1.3 Genetic predisposition to tumorigenesis 
Inherited predisposition is known for virtually every type of human cancer (Knudson 2002). The 
predisposed individual carries a defect in the germline, such as a mutated allele of a gene, which 
predisposes him or her to the formation of tumors. This predisposition can also be transferred to the 
offspring of the individual. Usually a certain amount of loss of germline mutations occurs in every 
generation, for example if the condition produces mortality before the end of the age of reproduction. 
However, mutational equilibrium can be attained by a low rate of occurrence of new germline 
mutations in the population (Knudson 2002, Weinberg 2007 p.43, 224-226). 
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There are currently about 100 genes known to cause Mendelian-inherited cancer syndromes (Cazier & 
Tomlinson 2010). Clinical characteristics of inherited cancer syndromes include, among others, a 
positive family history of cancer, a typical inheritance pattern of tumors, multiple primary tumors and 
early  age  of  onset  (D’Orazio  2010).  It  has  been  argued  that  these  syndromes  affect  about  1  %  of  
cancer patients, and in children it is estimated that 5 to 10% of cancer can be explained by a certain 
genetic mutation (Fearon 1997, D’Orazio 2010). Inherited predisposing mutations in oncogenes have 
been identified in several well-established syndromes that cause dominant heredity of cancer, such as 
RET mutations causing thyroid, parathyroid and adrenal tumors in multiple endocrine neoplasia type 
2A (MEN2A) (Mulligan et al. 1993, Salmela and Ebeling in Välimäki et al. 2009 p.474-480, Table 
1). Inherited mutations in tumor suppressor genes can also confer a dominant pattern of heredity. 
These include for example RB1 mutations causing retinoblastomas and FH mutations causing 
hereditary leiomyomatosis and renal cell cancer (HLRCC) (Knudson 1971, Tomlinson et al. 2002, 
Table 1). Hereditary cancer predisposition can also be caused by mutations in stability genes (also 
called caretakers), such as BRCA1 and BRCA2, resulting in dominant inheritance of breast and 
ovarian cancer, and FANCA mutations, causing recessive inheritance of leukemia (Butturini et al. 
1994, Futreal et al. 1994, Miki et al. 1994, Wooster et al. 1995, Vogelstein & Kinzler 2004). The 
known Mendelian-inherited cancer syndromes explain only a minor part of the familial clustering of 
cancers. Thus, in most cases, the increased familial relative risk of cancer must involve several risk 
alleles with low or moderate penetrance (Cazier & Tomlinson 2010). It has indeed been estimated in 
twin studies that hereditary factors could significantly contribute to prostate cancer (42% of risk may 
be explained by heritable factors), colorectal cancer (35%) and breast cancer (27%) (Lichtenstein et 
al. 2000).    
It is known that a certain germline mutation does not suffice for carcinogenesis, but subsequent 
somatic mutations are required. These can be caused by various environmental factors, such as 
ionizing radiation, dietary factors and consumption of tobacco. These factors can also affect the 
penetrance of cancer, i.e. the proportion of genetically predisposed individuals that ultimately develop 
tumors (Knudson 2002, Weinberg 2007 p.47, Cazier & Tomlinson 2010).  
2. The pituitary gland 
The pituitary gland is a crucial part of the endocrine system. It co-ordinates the body’s internal 
physiology, regulates its development throughout life and helps it to adapt to change in the external 
environmental by secreting hormones that act on their target tissues (Brook & Marshall 2001 p.34). 
The pituitary is composed of three lobes: the anterior lobe (adenohypophysis; contains the pars 
distalis and pars tuberalis) is mainly glandular tissue; the posterior lobe (neurohypophysis; contains 
the pars nervosa and infundibulum) is neural tissue that stores oxytocin and antidiuretic hormone; and 
between them the intermediate lobe (pars intermedia), which is atrophic in humans (Sane in Välimäki 
et al. 2009 p.76-77). The pituitary lies in a bony cavity, the sella turcica of the sphenoid bone. It is 
connected to the overlying hypothalamus by a stalk that carries a system of portal veins from the 
hypothalamus to the pituitary, as well as axons to the neurohypophysis (Brook & Marshall 2001 p.35-
37).  
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During embryogenesis, the pituitary emerges from two distinct ectodermal components. One of these 
is the Ratkhe’s pouch, a dorsal outgrowth of the buccal cavity, which forms the anterior pituitary. The 
second is a downgrowth of neuroectoderm from the floor of the third ventricle, which develops into 
the pituitary stalk and the posterior pituitary (Brook & Marshall 2001 p.35). The distinct cell types of 
the anterior pituitary arise from a pool of self-renewing and proliferating progenitor cells present in 
the epithelium of Ratkhe’s pouch (Vankelecom 2010). Mitotic activity of the adult pituitary is seen in 
1-2% of cells that are active oligopotent stem cells. They undergo mitoses at a steady rate that 
gradually decreases with age (Levy 2008). Interestingly, the adult pituitary seems to retain plasticity 
and is able to flexibly remodel its hormone-producing cell compartment in response to changing 
endocrine demands, for example during pregnancy and puberty. Recently, plausible candidates for 
stem cells  of  the  adult  pituitary  have  been  proposed,  that  express  stem cell-associated  markers  and  
signaling factors, and display multipotency and a niche-like organization (Vankelecom 2010).  
The anterior pituitary contains five populations of secretory cells that secrete by exocytosis the six 
pituitary hormones into the bloodstream. Growth hormone (GH) is secreted by somatotrophs, 
prolactin (PRL) by lactotrophs, thyroid-stimulating hormone (TSH) by thyrotrophs, 
adrenocorticotropic hormone (ACTH) by corticotrophs, and both luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) are secreted by gonadotrophs. FSH and LH are dimeric proteins 
that share a common alpha subunit (aSU), but their beta subunits (bSU) are unique and derived from 
different genes encoding distinct proteins (Brook & Marshall 2001 p.38, Ooi et al. 2004, Bernard et 
al. 2010, Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pituitary gland. A schematic presentation of the cells in the anterior pituitary, the hormones 
they secrete, and the target tissues and main effects of these hormones. Modified from Ooi et al. 2004 
with the permission from Elsevier. 
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The anterior pituitary lies under the stringent control of the hypothalamus, which controls the release 
of pituitary hormones by releasing hypothalamic hormones such as growth hormone-releasing 
hormone (GHRH) and gonadotropin-releasing hormone (GNRH) to the hypophysial portal 
vasculature. In addition, some neuromessengers can directly control the release of pituitary hormones; 
for example dopamine is the main inhibitor of PRL secretion. Also feedback effects of systemic 
circulating hormones and cytokines acting in a paracrine or autocrine fashion regulate the secretion of 
pituitary hormones. (Crowley 1999, Brook & Marshall 2001 p. 38-40, Haedo et al. 2009, Sane in 
Välimäki et al. 2009 p.69, 75-76). 
3. Pituitary adenomas 
3.1 Benign adenomas of the anterior lobe 
Pituitary adenomas account for about 15% of intracranial neoplasms. They can arise from any cell 
type(s) of the anterior pituitary and accordingly present a variety of clinical manifestations based on 
their size, location and function. Frequently encountered clinical manifestations relate to excessive 
hormone secretion of the tumor, hormone deficits of the pituitary hormones (i.e. hypopituitarism) and 
expansion of the tumor mass. However, pituitary adenomas can also be asymptomatic. Although some 
adenomas are invasive, the vast majority of them are considered as histologically benign lesions, and 
they metastasize exceedingly rarely. Recent advances in molecular biology, immunocytochemistry 
and imaging, and the introduction of new treatment options have improved the knowledge of these 
adenomas and their management (Arafah & Nasrallah 2001, Melmed 2003, Karhu & Aaltonen 2007, 
Sane in Välimäki et al. 2009 p.98-126).  
3.2 Incidence and prevalence  
According to data obtained from autopsy and radiological imaging series, pituitary adenomas occur 
very commonly in the general population. Most of these tumors are found incidentally and present no 
obvious clinical impact (Daly et al. 2009). In an early study on pituitary adenoma prevalence, 
adenomas were found in nearly one in every four autopsy cases (Costello 1936). In a recent 
systematic review, the overall prevalence of pituitary adenomas was found to be 16.7% (14.4% based 
on autopsy studies and 22.5% based on radiological studies) (Ezzat et al. 2004). Incidence rates of 
pituitary adenomas generally increase with age and are higher in women in early life and higher in 
men in later life. The difference in incidence rates between sexes could be due to their different 
symptomatology, such as earlier and more noticeable symptoms of hyperprolactinemia in women (e.g. 
amenorrea and galactorrhea). Men are on average diagnosed with larger tumors than women since 
their diagnosis may be delayed, giving the tumor a chance to grow larger before clinical detection 
(Ciccarelli et al. 2005, McDowell et al. 2010). Also race may affect the incidence of pituitary 
adenomas, for example incidence rates for women of African descent are about three times as high as 
for Caucasian women (Heshmat et al. 1976). The overall incidence rate of pituitary adenomas in the 
United States has been noted to be 2.7 cases per 100 000 patient years in 2004-2007 (McDowell et al. 
2010). In contrast, incidences noted in England have been lower, only 0.75 cases per 100 000 patient 
years in 1999-2003. In England, there has been a pattern of initial increase (0.91 per 100 000 in 1989-
1993) followed by stabilization, and this change in incidence has mainly been seen in the elderly age 
group (Arora et al. 2010). In Northern Finland, overall incidence of pituitary adenomas in 1992-2007 
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was 4.0 cases per 100 000 patient years, with a gender-specific incidence of 2.2 per 100 000 in males 
and 5.9 per 100 000 in females (Raappana et al. 2010).   
3.3 Tumor classification 
Pituitary adenomas are traditionally classified as microadenomas if they are <10mm in diameter and 
located totally within the sella turcica, in contrast to macroadenomas that are >10mm in diameter and 
can be totally intrasellar, but are often associated with extrasellar extension. In addition, giant 
adenomas have been defined as extending >40mm from the midpoint of the jugum sphenoidale or 
extension to within 6mm of the foramen of Monro (Majós et al. 1998, Arafah & Nasrallah 2001). 
However, the general classification of pituitary adenomas is based on characteristics of hormone 
staining, electron microscopic changes, clinical signs and symptoms. Hereby, adenomas are classified 
as prolactinomas, somatotropinomas, adrenocorticotropinomas, gonadotropinomas, thyrotropinomas, 
null-cell adenomas and oncocytomas (Arafah & Nasrallah 2001, Table 2). The World Health 
Organization’s complete clinicopathological five-tier scheme for pituitary adenoma classification 
includes assessment of endocrine activity, imaging, operative findings, histology, 
immunocytochemistry and ultrastructure of the pituitary adenoma (Kovacs et al. 1996). 
Table 2. Classification and characteristics of pituitary adenoma types. Modified from Arafah & 
Nasrallah with the permission from the Society for Endocrinology, data also from Sane in Välimäki et 
al. 2009 p.100 and Melmed 2003.   
Tumor type Secretion Prevalence Symptoms of hormone secretion Laboratory diagnosis 
 Prolactinoma PRL 27-45% hypogonadism, galactorrhea S-PRL? 
 Somatotropinoma GH 15-20% acromegaly, gigantism OGTT, S-IGF-I?, S-GH? 
 Adrenocorticotropinoma 
 
ACTH 
 
9-12% 
 
Cushing's disease 
 
Dexamethasone test,  
24hUFC? 
 Gonadotropinoma 
 
LH, FSH, 
a/bSU 
9-15% 
 
none, hypergonadism or 
hypogonadism 
S-FSH?, S-LH?, S-a/bSU? 
 
 Thyrotropinoma TSH 1-2% hyperthyroidism TRH test, T??, T??, TSH? 
 NFPA¹ none 5-25% none none 
 PRL, prolactin; GH, growth hormone;  ACTH, adrenocorticotropic hormone; LH, luteinizing hormone; FSH,  
follicle-stimulating hormone; a/bSU, alpha/beta subunit; TSH, thyroid-stimulating hormone; NFPA, non- 
functioning pituitary adenoma; OGTT, oral glucose tolerance test; S-IGF-I, serum insulin-like growth  
factor 1; TRH, thyrotropin-releasing hormone; T?, triiodothyronine T?, thyroxine; UFC, urinary free cortisol 
¹ Including null-cell adenomas and oncocytomas  
  
    
    
3.4 Clinical features and diagnosis  
The majority of pituitary adenomas are asymptomatic and have no clinical impact (Daly et al. 2009). 
However, based on population studies the prevalence of clinically relevant adenomas is higher than 
previously thought at about 94 in 100 000 patients in the general population (Clayton 1999, Daly et al. 
2006b). In addition to hormone hypersecretion, there are two main mechanisms by which pituitary 
adenomas can cause clinical symptoms. These are compressive pituitary failure, causing e.g. 
hypogonadism, thyroid failure or adrenal failure, and central mass effects, causing e.g. visual field 
disturbances, headaches and cranial nerve palsies (Melmed 2003).   
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Prolactinomas are the most common type of pituitary adenomas, accounting for 27-45% of all 
pituitary adenomas (Arafah & Nasrallah 2001, Sane in Välimäki et al. 2009 p.100, Table 2). 
However, even higher prevalence of prolactinomas (66.2% of pituitary adenomas) has been suggested 
(Daly et al. 2009). Prolactinomas occur more frequently in women than men until after the fifth 
decade of life when their frequency equalizes between the sexes (Mindermann & Wilson 1994). The 
most common clinical features of prolactinomas are hypogonadism and/or galactorrhea in both males 
and females, and they cause amenorrhea, oligomenorrhea or infertility in females and decreased libido 
or diminished sexual potency in males. Due to this different symptomatology in sexes, women usually 
present earlier than men and often exhibit microprolactinomas at diagnosis; men present later and 
with a higher frequency of macroprolactinomas and attendant mass effects (Ciccarelli et al. 2005). 
The diagnosis is based on symptoms, an elevated serum PRL (S-PRL) level and magnetic resonance 
imaging (MRI). Other causes of hyperprolactinemia should be ruled out in prolactinoma diagnostics, 
such as pregnancy and consumption of certain medications (Colao 2009). 
GH-secreting somatotropinomas account for approximately 15-20% of pituitary adenomas and cause 
acromegaly in adults and gigantism if they occur in children before epiphyseal plate fusion (Arafah & 
Nasrallah 2001, Keil & Stratakis 2008, Sane in Välimäki et al. 2009 p.100, Table 2). The incidence of 
somatotropinomas is about 3-4 cases in a million patient years (Lissett et al. 1998, Kauppinen-
Mäkelin et al. 2005). About 25% of somatotropinomas also co-secrete PRL. These mixed adenomas 
can be dimorphous adenomas composed of GH and PLR cells. They can also be monomorphous 
mammosomatotroph adenomas derived from mammosomatotrophs that can secrete both GH and 
PRL. A third possibility is that they are derived from a more primitive acidophil stem cell, which is 
the progenitor of somatotrophs and lactotrophs. The clinical manifestations of acromegaly are derived 
from the major organ systems of the body: the musculosceletal, integumentary, gastrointestinal, 
cardiovascular, pulmonary, endocrine and metabolic systems. Symptoms can be subtle signs of acral 
overgrowth (arthralgias, jaw prognathism and frontal bone bossing), soft-tissue swelling, fasting 
hyperglycemia and hyperhidrosis. At the other end of the spectrum are symptoms of florid 
osteoarthritis, diabetes mellitus, hypertension and respiratory and cardiac failure. Before epiphyseal 
plate closure, excessive GH leads to linear growth acceleration and gigantism (Melmed 2006, Sane in 
Välimäki et al. 2009 p.113-116). The mortality rate of acromegalics is double that of the general 
population. However, it has been reported that mortality reverts to expected levels when there is 
reduction of GH to less than 1µg/l or normalization of insulin-like growth factor 1 (IGF-I), which is 
the prime mediator of the effects of GH on target tissues (Holdaway et al. 2004). In a survey of 
mortality in acromegaly in Finland, posttreatment GH less than 2.5µg/l was associated with a normal 
life-span (Kauppinen-Mäkelin et al. 2005). Apart from typical symptoms and imaging, the diagnosis 
of acromegaly can be based on the inability of the patient to suppress GH levels during an oral 
glucose-tolerance test (OGTT), the excessive peripheral biologic effects of GH reflected by elevations 
in S-IGF-I levels, as well as elevated S-GH levels (Melmed 2006, Sane in Välimäki et al. 2009 p.116-
119).  
ACTH-secreting adenomas, known as adenocorticotropinomas, account for 9-12% of pituitary 
adenomas and are seen predominantly in females. They cause Cushing’s disease, a state of 
hypercortisolism caused by excess pituitary secretion of ACTH, which stimulates the secretion of 
cortisol by the adrenal glands. Symptoms of hypercortisolism include central obesity, easy bruising, 
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proximal myopathy, striae, hypertension, hirsutism, menstrual irregularity, mood changes, poor 
wound healing, osteoporosis and hyperglycemia. Initial screening of suspected Cushing’s disease 
patients is achieved by an overnight 1-1.5mg dexamethasone suppression test where dexamethasone 
fails  to  suppress  S-cortisol  levels  in  Cushing’s  patients,  or  a  24h  urinary  free  cortisol  (UFC)  
measurement, followed by pituitary MRI (Arafah & Nasrallah 2001, Sane in Välimäki et al. 2009 
p.100, Table 2).   
Gonadotropinomas account for 9-15% of pituitary adenomas. They can secrete LH, FSH or both, or 
their respective subunits aSU and bSU. However, their hormone secretion is often minimal or 
inefficient and the clinical behavior is thus often that of an inactive tumor (Samuels & Ridgway 
1995). If present, the most common clinical presentations of gonadotropinomas are related to 
mechanical effects of the expanding macroadenoma, and it is common that the adenomas are large 
and extend beyond the sella turcica at diagnosis. In rare cases, patients may have symptoms of 
excessive hormone secretion, for example increased libido in men and ovarian hyperstimulation 
syndrome in women (Arafah & Nasrallah 2001, Table 2). Diagnosis of gonadotropinomas is based on 
measurements of serum hormone concentrations of intact FSH, intact LH and a/bSU, and tumor 
imaging with MRI (Daneshdoost et al. 1991, Young et al. 1996, Arafah & Nasrallah 2001). 
Thyrotroph adenomas that secrete TSH are rare, accounting for 1-2% of pituitary adenomas. Patients 
often have goiter and evidence of mild hyperthyroidism, such as hyperhidrosis and increased appetite. 
By the time of diagnosis, tumors are often large and have extrasellar extension, causing signs of 
hyperthyroidism and symptoms of mechanical compression. However, 30% of tumors also show 
increased secretion of GH or PRL, which can complicate the symptoms in these patients. Diagnosis of 
thyrotropinomas is based on increases in S-TSH and the serum thyroid hormone levels thyroxine (T4) 
and triiodothyronine (T3). Also a thyroid-releasing hormone (TRH) stimulation test without a rise in 
S-TSH indicates the possibility of a thyrotropinoma, and diagnosis should be followed with MRI 
scanning (Arafah & Nasrallah 2001, Roelfsema et al. 2009, Sane in Välimäki et al. 2009 p.123-124, 
Table 2). 
Approximately 30% of pituitary adenomas are endocrinologically silent i.e. they cause no clinical 
symptoms related to excessive hormone secretion. These are often true non-functioning pituitary 
adenomas (NFPA) that include null-cell adenomas or oncocytomas. They usually present with 
mechanical effects of the adenoma and variable degrees of hypopituitarism, and their diagnosis is 
based on MRI scanning (Arafah & Nasrallah 2001, Heaney & Melmed 2004; Sane in Välimäki et al. 
2009 p.125, Table 2). 
3.5 Treatment and management 
Goals in the treatment of pituitary tumors include controlling clinical and biochemical signs of 
excessive hormone secretion, preserving normal pituitary function whenever possible, reversing or 
treating impaired pituitary function and controlling the growth of the tumor and its mechanical effects 
on surrounding structures (Arafah & Nasrallah 2001).  
In most pituitary adenomas, the primary treatment approach is transsphenoidal surgical 
adenomectomy. Generally, it is a very effective operation with low morbidity and mortality. However, 
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a subsequent transsphenoidal approach may be needed to resect the residual suprasellar part of the 
tumor that descended after the first operation. A craniotomy may be needed in patients with a 
residual, suprasellar tumor that did not descend during transsphenoidal approaches. Repeated 
operations may also be needed if there is recurrence of the tumor. Radiation therapy is rarely 
recommended as the primary form of treatment, but it can be used as an adjunctive therapy in selected 
patients (Landolt 1999, Arafah & Nasrallah 2001, Sane in Välimäki et al. 2009 p.103). If 
hypopituitarism persists after surgery, it is managed by replacement of the deficient hormone(s) 
(Arafah & Nasrallah 2001, Melmed 2003). 
There  is  also  medical  therapy  available  for  the  treatment  of  many  types  of  pituitary  adenomas.  For  
example, the dopamine agonists bromocriptine and cabergoline reduce the size and hormonal 
hypersecretion of prolactinomas, and they are most often the primary treatment of prolactinomas. In 
acromegaly patients, the first-line pharmacological treatment is somatostatin analog (SSA) therapy. 
SSAs are beneficial especially in patients with post-operative residual tumor activity, or in patients 
who are poor surgical candidates. Patients are most often treated with octreotide or lanreotide, which 
reduce plasma GH and IGF-I concentrations and in some cases also cause a moderate decrease in 
tumor size. In addition, a novel SSA, pasireotide, is currently in clinical trials. Also chimeric 
compounds with both somatostatin receptor and dopamine receptor affinity are being developed.  
Novel drugs also include pegvisomant, a GH receptor antagonist that can be used for treatment of 
persistently high IGF-I levels and that can also be used in combination therapy with SSAs (Barkan et 
al. 1988, Molitch et al. 1997, Arafah & Nasrallah 2001, Manjila et al. 2010). 
Recurrence of pituitary adenomas after apparently complete surgical resection is reported in 10-25% 
of patients, usually within the first four years of operation. Therefore, periodic hormonal testing and 
repeated imaging studies are recommended to pituitary adenoma patients. It has further been 
recommended that follow-up of patients is maintained indefinitely (Arafah & Nasrallah 2001, Sane in 
Välimäki et al. 2009 p.126, 128).  
Apart from clinically relevant adenomas that require effective treatment, some pituitary adenomas are 
found incidentally by radiological imaging of asymptomatic patients. These tumors are called 
incidentalomas. Their management is suggested to be based on periodic hormonal, clinical and 
radiological follow-up, particularly in cases having neither hormonal abnormalities nor clinical signs 
of the incidentaloma (Daly et al. 2007a).  
4. Genetics of pituitary adenomas 
Pituitary adenomas arise from the monoclonal expansion of a pituicyte that evades apoptosis and 
acquires unlimited replicative potential. Etiologic factors that have been implicated in pituitary 
tumorigenesis include genetic events, hormonal stimulation and growth factors. It is likely that all of 
these interact to initiate transformation and promote tumor-cell proliferation (Melmed 2003, Asa & 
Ezzat 2009, Tanase et al. 2009). In the following sections, a number of genetic aberrations are 
described that are encountered either as somatic events in sporadic pituitary adenomas or as inherited 
defects in the context of familial susceptibility to pituitary tumors.    
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4.1 Sporadic pituitary adenomas 
The vast majority of pituitary adenomas are sporadic. Their tumorigenesis has been studied with for 
example candidate gene approaches, genome-wide allelotyping and comparative genomic 
hybridization. The studies have identified LOH at putative tumor suppressor gene loci, putative 
markers of tumor progression and early alterations in tumors. Also hotspots that may indicate an 
unstable chromatin structure that is susceptible to deletions or epigenetic gene-silencing events and 
chromosomal aberrations have been discovered (Simpson et al. 2003, Pack et al. 2005). However, in 
many cases it is still unclear which of these alterations are involved in initiation and progression of 
sporadic pituitary oncogenesis. 
4.1.1 GNAS/gsp oncogene 
The guanine nucleotide-binding protein alpha stimulating activity polypeptide (GNAS) gene (20q13) 
encodes the guanosine nucleotide-binding protein Gs?. It is required for the activation of adenylyl 
cyclase and subsequent generation of cyclic adenosine monophosphate (cAMP) in the cell. Acting as 
a cellular second messenger, cAMP binds to the cAMP-dependent protein kinase A (PKA) receptor 
and regulates a vast number of cellular processes, such as cell proliferation, differentiation and 
apoptosis. Activating mutations in GNAS cause increased activity of Gs?, leading to increased cAMP 
levels (Vallar et al. 1987, Akintoye et al. 2002, Chin et al. 2002, Boikos & Stratakis 2007b). The term 
gsp oncogene has been assigned to these activating GNAS mutations due to their association with 
certain neoplasms. The gsp oncogene is found in 30-40% of GH-secreting adenomas, in a low 
percentage of NFPA and ACTH-secreting adenomas and in differentiated thyroid carcinomas. In 
addition, it is reported that Gs? messenger ribonucleic acid (mRNA) levels can be high in some 
somatotropinomas without the gsp oncogene itself. The increased production of cAMP conferred by 
these mutations leads to overactivation of specific pathways involved in cell proliferation and specific 
programs of cell differentiation (Landis et al. 1989, Spada et al. 1998, Picard et al. 2007).  
McCune-Albright syndrome (MAS) is a rare sporadic condition characterized by a triad of café-au-lait 
skin pigmentation, polyostotic fibrous dysplasia of the bone and hyperfunctioning endocrinopathies. 
These include excess GH, hyperthyroidism and Cushing’s syndrome. The molecular etiology of this 
genetic but not inherited disease is an early embryonic postzygotic activating mutation of GNAS that 
results in constitutive Gs? activation and elevated cAMP levels in the affected individual (Vallar et al. 
1987, Akintoye et al. 2002, Boikos & Stratakis 2007b). 
4.1.2 Other features of sporadic adenomas 
Apart from the well-defined GNAS/gsp oncogene activation in sporadic pituitary adenomas, research 
of other pathways and factors is vigorously on-going. Putative mechanisms in sporadic pituitary 
tumorigenesis involve classic oncogenic signals, dysregulated growth factors and their receptors, 
epigenetically silenced tumor suppressor genes and chromatin remodeling (Asa & Ezzat 2009). 
Examples of these mechanisms include activation of the proto-oncogene pituitary tumor transforming 
gene (PTTG), downregulation of the fibroblast growth factor receptor (FGFR) 2 or inactivation of 
RB1 (Woloschak et al. 1996, Abbass et al. 1997, Hunter et al. 2003). There are also other proteins 
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emerging in recent studies, that may be involved in pituitary tumorigenesis, such as inhibitor of 
apoptosis stimulating protein of p53 (iASPP) and RWD-containing sumoylation enhancer (RSUME) 
(Fuertes et al. 2010, Pinto et al. 2010).    
4.2 Familial pituitary adenomas 
A minority (~5%) of pituitary adenomas occurs in a familial setting. The identification of genetic and 
molecular mechanisms underlying these conditions has greatly improved the understanding of them. 
This process classically involves initial linkage analysis studies, the mapping and identification of 
relevant gene(s) and deciphering how abnormal protein expression leads to neoplastic changes at the 
molecular level (Daly et al. 2005, Tichomirowa et al. 2009). In the following sections, four familial 
conditions will be outlined where a known genetic defect leads to pituitary tumorigenesis. The two 
last sections will focus on familial pituitary adenomas with a yet unknown genetic background.  
4.2.1 Multiple endocrine neoplasia type 1 (MEN1) 
Multiple endocrine neoplasia type 1 (MEN1) (OMIM 131100) is an autosomal dominant disorder 
characterized by different combinations of tumors in the parathyroids, pancreas and the anterior 
pituitary. In addition, some patients may develop adrenal cortical tumors, gastrointestinal  
or thoracic neuroendocrine tumors, facial angiofibromas, collagenomas and lipomas. MEN1 arises 
from germline mutations in the MEN1 gene (11q13) (Chandrasekharappa et  al. 1997, Elston et al. 
2009, Thakker 2010, Table 3). Pituitary adenomas occur in about 30% of patients. Most often these 
are prolactinomas, although somatotropinomas, corticotropinomas or NFPAs are occasionally 
diagnosed as well (Trump et al. 1996, Tichomirowa et al. 2009, Thakker 2010). The prevalence of 
MEN1 has been estimated to be 0.02 – 0.2 in 1000 (Cazabat et al. 2009). MEN1 is characterized as 
familial if an affected individual has at least two of the three above-mentioned main MEN1 tumors 
and at least one first-degree relative has one of the three tumors (Marx et al. 1999, Brandi et al. 2001). 
Although most MEN1 patients have inherited the disorder, molecular genetic studies have confirmed 
de novo mutations of the MEN1 gene in approximately 10% of patients with MEN1 (Lemos & 
Thakker 2008). Approximately 10% of clinically suspected MEN1 patients do not have MEN1 
mutations, suggesting that other predisposition genes may play a role in this phenotype (Hai et al. 
2000; Daly et al. 2005). 
The MEN1 gene consists of 10 exons encoding a 610 aa protein referred to as menin. It is a 
predominantly nuclear protein that has a role in transcriptional regulation, genome stability, cell 
division and proliferation. MEN1-associated tumors frequently exhibit LOH at the MEN1 locus, 
which is consistent with the tumor suppressor role of MEN1. Furthermore, although occasional 
somatic abnormalities of MEN1 have been reported in endocrine tumors, MEN1 is very rarely mutated 
in sporadic pituitary adenomas (Chandrasekharappa et al. 1997, Zhuang et al. 1997, Thakker 2010). 
To date, over 1300 MEN1 mutations have been identified, of which the majority are predicted to lead 
to the truncation of menin. Interestingly, the phenotype of MEN1 is variable and shows an absence of 
phenotype-genotype correlations. Therefore, clinical features vary between patients of MEN1 
families, even between identical twins (Bahn et al. 1986, Lemos & Thakker 2008, Thakker 2010). 
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Table 3. Familial conditions with pituitary adenomas, data from Vierimaa et al. 2006, Agarwal et al. 
2009, Tichomirowa et al. 2009, Gadelha & Frohman 2010, Kirschner 2010 and Thakker 2010. 
Condition Predisposing gene (locus) Pituitary adenomas 
 MEN1 MEN1 (11q13) 30% of patients; mostly prolactinomas 
 MEN4 CDKN1B (12p13) few patients discovered; some present 
 
 
p15 (9p21), p18 (1p32), p21 (6p21)? with pituitary adenomas (GH, ACTH) 
 CNC PRKAR1A (17q22-24)  10% GH-secreting adenomas ; 75% 
 
 
unidentified (2p16) show  GH/PRL overactivity 
 PAP AIP (11q13) low penetrance of pituitary adenomas; 
 
  
mostly GH-secreting adenomas 
 IFS AIP (11q13) in ~40%; unidentified acromegaly; gigantism 
 FIPA AIP (11q13) in ~15%; unidentified all pituitary tumor types; GH- and PRL-  
     secreting adenomas the most common 
  
4.2.2 MEN4 (MEN1-like syndrome) 
A recessively inherited MEN-like syndrome (MENX), causing multiple endocrine cancers including 
pituitary tumors, was first identified when occurring spontaneously in the rat. The MENX gene was 
later  shown  to  be  cyclin-dependent kinase n1b (cdkn1b) (Fritz et al. 2002, Piotrowska et al. 2004, 
Pellegata et al. 2006). In humans, the corresponding CDKN1B encodes the protein cyclin-dependent 
kinase inhibitor p27Kip1 on chromosome 12p13. The first heterozygous germline CDKN1B mutation 
(W76X) was found in a German family with acromegaly, primary hyperparathyroidism, renal 
angiomyolipoma and testicular cancer. Pedigree analysis revealed mutation segregation with the 
phenotype. Although the wildtype allele was retained in the tumor tissue, immunohistochemical 
staining of p27Kip1 showed no protein expression in the tumors. This supported an association between 
germline CDKN1B mutations and a heritable human MEN1-like condition called MEN4 (OMIM 
610755) (Pellegata et al. 2006, Table 3). So far, only a handful of CDKN1B mutations have been 
found in suspected MEN1 cases with no MEN1 mutations (Georgitsi et al. 2007b, Agarwal et al. 
2009). Interestingly, one of these (K25fs) was in a patient with an ACTH-secreting adenoma, but 
three others (P95S, -7G>C and X>Q) were in patients with no pituitary manifestation (Georgitsi et al. 
2007b, Agarwal et al. 2009).   
The CDKN1B gene consists of three exons encoding 198 aa. It is a well-established cyclin-dependent 
kinase inhibitor that negatively regulates cell cycle progression by inhibiting cyclin and cyclin-
dependent kinase complexes in the nucleus (Pellegata et al. 2006, Lee & Kim 2009). It is reported that 
p27Kip1 is underexpressed or even absent in most pituitary adenomas (Lidhar et al. 1999). Intriguingly, 
the regulation of p27Kip1 expression involves both menin, and aryl hydrocarbon receptor interacting 
protein (AIP) through aryl hydrocarbon receptor (AHR) (Kolluri et al. 1999, Karnik et al. 2005, Milne 
et al. 2005, see section 5.2.1). The precise role and pathways of p27Kip1 in pituitary tumorigenesis are, 
however, yet to be elucidated. Interestingly, Besson et al. reported that independently of its role as a 
CDK inhibitor and tumor suppressor, p27Kip1 can act as an oncogene in vivo, promoting stem cell 
expansion and tumorigenesis in multiple tissues (Besson et al. 2007). In addition, there are reports of 
variations in other CDK inhibitor genes (p15, p18 and p21)  that  have  been  suggested  to  lead  to  a  
MEN1-like phenotype (Agarwal et al. 2009).   
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4.2.3 Carney complex (CNC) 
Carney complex (CNC) (OMIM 160980) is a complex of myxomas, schwannomas, spotty skin 
pigmentation and endocrine overactivity (Carney et al. 1985, Tichomirowa et al. 2009, Table 3). It is 
a rare autosomal dominant disease that has been described in about 500 patients (Boikos & Stratakis 
2007a). The median age at diagnosis is about 20 years, and the most common clinical manifestation at 
the time of presentation is spotty skin pigmentation. CNC patients have a decreased life-span, mostly 
due to heart-related causes such as cardiac myxomas (Stratakis et al. 2001). The main endocrine 
abnormalities seen in CNC are primary pigmented nodular adrenocortical disease, thyroid tumors and 
nodules, testicular tumors and acromegaly (Stergiopoulos & Stratakis 2003). Acromegaly occurs in 
roughly 10% of cases, but even 75% of patients have elevated GH, IGF-I or PRL levels or abnormal 
responses to dynamic pituitary testing (Pack et al. 2000, Stratakis et al. 2001). CNC-related 
acromegaly is distinguished by multifocal hyperplasia of mammosomatotropic cells that includes 
nonadenomatous pituitary tissue within the tumors (Kurtkaya-Yapicier et al. 2002). 
Two candidate gene loci have been identified, one on chromosome 17q22-24 and the other on 
chromosome 2p16 (Stratakis et al. 1996, Casey et al. 1998). While no predisposing gene(s) have been 
found in the 2p16 locus, the 17q22-24 locus contains the gene encoding PKA regulatory subunit 1 
alpha (PRKAR1A), which comprises 11 exons and encodes a protein of 381 aa. Mutations in 
PRKAR1A have been identified in up to 65% of CNC patients (Stratakis et al. 1996, Veugelers et al. 
2004). PRKAR1A is a tumor suppressor gene, and most PRKAR1A mutations lead to mRNA 
instability, decreased or absent protein expression, and PRKAR1A haploinsufficiency in CNC tumors 
(Kirschner et al. 2000). LOH at 17q22-24 and allelic loss have been shown in CNC tumors. 
PRKAR1A is the main component of PKA, which regulates most of the kinase activity catalyzed by 
the PKA holoenzyme in response to cAMP. This pathway is involved in the regulation of metabolism, 
cell proliferation, differentiation and apoptosis. The loss of PRKAR1A function enhances signaling 
through  the  PKA  pathway.  In  the  pituitary,  the  GHRH  receptor  uses  the  cAMP/PKA  pathway  to  
stimulate synthesis and the release of GH, suggesting that this could be one mechanism involved in 
the oncogenesis of somatotropinomas (Mayo et al. 1995, Kirschner et al. 2000, Groussin et al. 2002, 
Bossis & Stratakis 2004, Kirschner 2010). 
4.2.4 Pituitary adenoma predisposition (PAP) 
A fourth condition with familial pituitary adenomas, designated as pituitary adenoma predisposition 
(PAP) (OMIM 102200), was discovered by Vierimaa et al. in  2006  in  three  clusters  of  familial  
pituitary adenomas from Northern Finland. Two of the clusters could be linked by genealogy data. 
The patients displayed low-penetrance susceptibility to somatotropinomas, prolactinomas and mixed 
adenomas. To identify the predisposing gene, whole-genome single nucleotide polymorphism (SNP) 
genotyping was performed. This was followed by linkage analysis, which provided evidence for 
linkage in 11q12-11q13, a region also previously implicated in isolated familial somatotropinoma 
(IFS) (Gadelha et al. 1999, Gadelha et al. 2000, Soares et al. 2005, Vierimaa et al. 2006).  
The candidate locus was fine-mapped and the two pedigrees shared the linked haplotype, which 
segregated perfectly with somatotropinomas. Out of the 295 genes in the linked region, expression 
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profiles showed the lowest values for probes representing aryl hydrocarbon receptor interacting 
protein (AIP), also named aryl hydrocarbon receptor-associated protein-9 (ARA9) or hepatitis B virus 
x-associated protein 2 (XAP2). AIP was chosen as the prime candidate for mutation analysis. A 
protein-truncating AIP mutation (Q14X) was found to perfectly segregate with the GH-secreting 
adenoma phenotype in both of the families (Vierimaa et  al. 2006, Table 3). AIP screening was also 
performed on 45 acromegaly patients in a population-based cohort in Northern Finland that included 
four cases from the two families (Kauppinen-Makelin et al. 2005, Vierimaa et al. 2006). Six Q14X 
mutations and one intronic variable sequence (IVS) 3-1G>A mutation affecting the splice acceptor 
site of exon 4 were identified. Thus, AIP mutations accounted for 16% of the acromegaly patients in 
the population-based cases, and 40% of those that were diagnosed under the age of 35 years. In 
addition, two Q14X mutations were found in ten unselected Finnish sporadic acromegaly patients and 
a R304X mutation was found in Italian siblings with somatotropinomas (Vierimaa et al. 2006).  
AIP LOH in tumors was detected in all the mutation carriers that were studied in the study by 
Vierimaa et al., indicating a tumor suppressor role for AIP. The authors concluded that the penetrance 
of PAP appeared to be low and patients did not necessarily have a strong familial background of 
pituitary adenomas. The phenotype was characterized by young age at onset and occurrence of at least 
somatotropinomas, prolactinomas and mixed adenomas (Vierimaa et al. 2006). Since gene 
identification, studies have shown that AIP mutations are predominantly associated with 
somatotropinomas (Daly et al. 2007b, Georgitsi et al. 2008, Leontiou et al. 2008, Cazabat et  al. 
2009). AIP mutation screening has been performed in a variety of sporadic non-pituitary tumors, but 
no relevant AIP mutations have been found (Georgitsi et al. 2007a, Raitila et al. 2007). Interestingly, 
AIP LOH was recently reported in an adrenocortical carcinoma of an acromegaly patient with a R81X 
AIP germline mutation, suggesting putative AIP implication also in non-pituitary tumorigenesis 
(Toledo et al. 2010). However, the 11q13 LOH could also be accompanied by a germline defect in 
another, yet unidentified tumor suppressor gene at 11q13. Furthermore, the existence of such a gene 
related to adrenocortical tumorigenesis has strongly been suggested by previous genetic studies 
(Kjellman et al. 1999, Toledo et al. 2010). Interestingly, one recent report has also suggested MEN1 
and AIP deletions to be involved in the pathogenesis of brown fat tumors hibernomas (Nord et al. 
2010). 
The AIP gene (11q13) comprises six exons that encode a protein of 330 aa in length. AIP has a FK605 
binding protein (FKBP) homology domain in the amino-terminus, and the carboxy-terminal half 
contains three tetratricopeptide repeat (TPR) domains that mediate protein-protein interactions 
(Carver & Bradfield 1997, Petrulis & Perdew 2002). Since gene discovery, about fifty different AIP 
mutations have been identified, including deletions, insertions, frameshift, nonsense, missense, splice 
site and promoter mutations, as well as deletions of the whole AIP gene (Barlier et al. 2007, Cazabat 
et al. 2007, Daly et al. 2007b, Georgitsi et al. 2007a, Iwata et al. 2007, Naves et al. 2007, Raitila et al. 
2007, Toledo et al. 2007, Georgitsi et al. 2008, Leontiou et al. 2008, Montanana 2008, Yaneva 2008, 
Jennings et al. 2009, Khoo et al. 2009, Montanana 2009, Igreja et al. 2010, Naves et al. 2010, 
Stratakis et al. 2010, Toledo et al. 2010, Figure 2). However, some of these may be rare 
polymorphisms and not disease-causing mutations. The vast majority of the mutations result in the 
deletion of the C-terminal end of the AIP protein (stop codons or frameshifts resulting in stop 
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codons), although the missense variants and an in-frame segmental duplication mostly affect the TPR 
domains of the C-terminal ?-helix. These findings are supported by earlier data suggesting that the 
third TPR domain and the last five carboxy-terminal aa are necessary for the biological activity of 
AIP (Petrulis & Perdew 2002, Daly et al. 2007b, Leontiou et al. 2008). Based on the AIP mutation 
screening from apparently sporadic pituitary adenomas in several studies, the estimated prevalence of 
AIP mutations is 2% for all these patients and 2.7% for acromegaly patients (Vierimaa et al. 2006, 
Barlier et al. 2007, Cazabat et al. 2007, Georgitsi et al. 2007a, Iwata et al. 2007, Raitila et al. 2007, 
Toledo et al. 2007,  Buchbinder et al. 2008, Georgitsi et al. 2008, Leontiou et al. 2008, Montanana 
2008, Yaneva 2008, Chahal et al. 2010, Stratakis et al. 2010). Interestingly, no somatic AIP mutations 
have been found in pituitary adenomas to date (Barlier et al. 2007, Leontiou et al. 2008, Vargiolu et 
al. 2009, Chahal et al. 2010). However, the first apparently de novo AIP mutation was recently 
identified in a young prolactinoma patient (Stratakis et al. 2010).    
 
 
 
Figure  2. The AIP gene and reported mutations. The AIP variants are shown according to their 
location in the AIP gene. Exons are shown as numbered black boxes and different mutation types are 
color coded (see above). See references in Cain et al. 2010.  
4.2.5 Isolated familial somatotropinoma (IFS) 
Isolated familial somatotropinoma (IFS) (OMIM 102200) is defined by at least two individuals with 
acromegaly or gigantism in a family without diagnosis of MEN1 or CNC (Gadelha et al. 1999, Table 
3). The patients are typically young and are most often diagnosed with macroadenomas, of which 
about half co-secrete prolactin (Soares & Frohman 2004). In efforts to identify a predisposition locus, 
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LOH at 11q13 without MEN1 mutations was shown, and it was concluded that loss-of-function of a 
tumor suppressor gene distinct from MEN1 would be responsible for IFS (Gadelha et  al. 1999, 
Gadelha et al. 2000, Soares et al. 2005). Subsequently, this area was reported to contain truncating 
mutations in AIP (Vierimaa et  al. 2006). Since gene discovery, AIP mutations have been found in 
several IFS families (e.g. Daly et al. 2007b, Iwata et al. 2007, Leontiou et al. 2008). Approximately 
40% of the families with IFS harbor an AIP mutation. These tumors are diagnosed at a young age and 
are larger than tumors in IFS families without AIP mutations, indicating a more aggressive disease 
(Gadelha & Frohman 2010). 
4.2.6 Familial isolated pituitary adenoma (FIPA) 
Pituitary  tumors  that  occur  in  a  familial  setting  without  diagnosis  of  MEN1  or  CNC  constitute  a  
condition termed familial isolated pituitary adenoma (FIPA) (OMIM 102200) (Verloes et al. 1999, 
Daly et al. 2006a). Comprising all pituitary adenoma types, FIPA is a much broader entity than IFS. 
In FIPA, pituitary tumors of one type can present in the affected members of a family (homogeneous 
presentation) or affected members can have different types of tumors (heterogeneous presentation) 
(Daly et al. 2006a). The reported frequencies of different pituitary tumor types in FIPA families are: 
prolactinomas 41%, somatotropinomas 30%, NFPAs 13%, mammosomatotropinomas 7%, 
gonadotropinomas 4%, Cushing’s disease 4% and thyrotropinomas 1%. There is a first-degree 
relationship between affected family members in about 75% of FIPA families. The pituitary 
adenomas of FIPA patients generally occur about four years earlier than in their sporadic counterparts. 
Macroadenomas are seen in 63% of FIPA kindreds (Tichomirowa et al. 2009, Table 3).  
A study on FIPA patients revealed that 15% of families had germline AIP mutations. Patients with an 
AIP mutation were significantly younger at diagnosis than FIPA patients without an AIP mutation. 
Tumors were also larger in the AIP mutation positive families when compared with the remainder of 
the cohort. The existence of kindreds with a strong family history of pituitary adenomas and with no 
MEN1, PRKAR1A, CDKN1B or AIP mutations indicates that other, yet unidentified genes may 
underlie FIPA (Daly et al. 2007b, Tichomirowa et al. 2009). 
5. Molecular function of the AIP protein  
5.1 Features and function of AIP   
The AIP gene (11q13) comprises six exons and encodes a co-chaperone protein of 330 aa with a 
molecular mass of 38 kilodaltons (kDa). An FKBP homology domain is located in the amino-terminus 
of AIP and the carboxy-terminal half contains three TPR domains that mediate the various protein-
protein interactions of AIP (Carver & Bradfield 1997, Petrulis & Perdew 2002). AIP has a ubiquitous 
tissue distribution (Kuzhandaivelu et al. 1996). In the normal pituitary, AIP has been identified only 
in GH- and PRL-secreting cells, where it associates with cytoplasmic secretory vesicles. In sporadic 
pituitary tumors, however, AIP is expressed in somatotropinomas, prolactinomas, corticotropinomas 
and NFPAs. In these lesions, AIP resides in the cytoplasm, except for in somatotropinomas where it is 
expressed in secretory vesicles, similar to normal somatotrophs (Leontiou et al. 2008). Interestingly, 
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low AIP expression has recently been shown to be a better marker of invasiveness in sporadic 
somatotropinomas than the proliferation marker Ki-67 and p53 (Kasuki Jomori de Pinho et al. 2010).  
To date, the function of the AIP protein has been poorly characterized, although it has been evaluated 
regarding its putative tumor suppressor role and also in Aip knockout models. The tumor suppressor 
role of AIP is supported by the occurrence of LOH in pituitary adenomas of AIP mutation carriers and 
by the ability of transient overexpression of wildtype AIP to reduce cell proliferation in cell culture 
(Vierimaa et al. 2006, Leontiou et al. 2008). Mice with a homozygous Aip deletion have been 
reported to die of congenital cardiovascular abnormalities such as a double-outlet right ventricle, 
ventricular septal defects and pericardial edema during embryonal development at the embryonic age 
of E10.5-E14.5. Thus, AIP seems to have a crucial function during embryogenesis (Lin et al. 2007). 
In addition, a hypomorph mouse model expressing 10% of normal AIP did not show the severe 
congenital cardiovascular abnormalities seen in the Aip-null mice; however it had a patent ductus 
venosus, suggesting that AIP may have a role in AHR-mediated hepatovascular development. 
Heterozygous Aip mice did not manifest any congenital cardiovascular abnormalities (Lin et al. 
2008). The tumor phenotype or possible pituitary adenoma formation of Aip mice was not assessed in 
these two studies (Lin et al. 2007, Lin et al. 2008).  
5.2 AIP-related cellular pathways  
A number of studies have identified several cellular interaction partners of AIP (Table 4, Figure 3). 
However, the role of these proteins in AIP-mediated tumorigenesis is not yet clear and this should be 
evaluated in further studies. The following sections will present the interactions found thus far.   
5.2.1 Role of AIP in the xenobiotic response 
AIP is best characterized as having a role in AHR signaling in the xenobiotic response. AIP resides in 
the cytoplasm where it forms a complex with AHR and two 90kDa heat-shock proteins (HSP90) that 
are complexed with p23 (Carver & Bradfield 1997, Kazlauskas et al. 2000,  Figure  3).  AHR  is  a  
transcription factor that mediates the effects of environmental toxins that ultimately cause e.g. 
teratogenesis and tumor promotion (Bunger et al. 2003). However, AHR has also been suggested to 
have a physiologic role in cell proliferation and differentiation as well as in immune system and liver 
function (Barouki et al. 2007). AIP is involved in the cytoplasmic retention of AHR and decreases its 
proteosomal degradation by protecting it against ubiquitination (Meyer & Perdew 1999, Kazlauskas et 
al. 2000, Petrulis & Perdew 2002, Pollenz & Dougherty 2005). In the presence of ligands such as 
dioxins or dioxin-like chemicals, for example 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), AHR is 
shuttled to the nucleus where it forms a heterodimer with AHR nuclear translocator (ARNT), also 
called hypoxia inducible factor 1? (HIF1-?). The binding of the AHR-ARNT complex to sequences 
called dioxin response elements (DREs) regulates the transcription of a multitude of genes encoding 
e.g. drug metabolizing proteins such as cytochrome P450 (CYP) enzymes (Reyes et al. 1992, 
Hankinson 1995, Ramadoss & Perdew 2005). Under hypoxia, ARNT heterodimerizes with hypoxia 
inducible factor 1 alpha (HIF1-?) to form the HIF1 transcription factor that binds hypoxia response 
elements (HREs) to regulate target gene expression (Gu et al. 2000, Rankin & Giaccia 2008).   
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Table 4. Cellular interaction partners of AIP, modified from Chahal et al. 2010 with the permission 
from Elsevier. 
Interacting protein Putative effect of interaction Reference 
AHR-HSP90-p23 
 
Stabilization of AIP-HSP90-AHR complex in the  
cytoplasm, protection of AHR from ubiquitination 
Carver & Bradfield 
1997 
PDE4A5 Inhibition of PDE4A5 enzyme activity Bolger et al. 2003 
PDE2A Lowered cAMP levels and AHR retention in cytoplasm de Oliveira et al. 2007 
Survivin Elevation of anti-apoptotic threshold, regulation of  Kang & Altieri 2006 
 
survivin stablility 
 RET Inability of AIP to bind and protect survivin from degradation Vargiolu et al. 2009 
HBV X antigen 
  
Involvement of AIP pathway in virus-induced cell transformation 
 
Kuzhandaivelu et al. 
1996 
EBNA-3 Involvement of AIP pathway in virus-induced cell transformation Kashuba et al. 2000 
PPAR? 
 
Reduction of PPAR? activity 
 
Sumanasekera et al. 
2003 
TR?1 TR?1-mediated transcription of TRH   Froidevaux et al. 2006 
GR Delay of nuclear entry and inhibition of the transcriptional  Laenger et al. 2009 
 
activity of GR  
 TOMM20 Maintenance of import competency of the mitochondrial  Yano et al. 2003 
 
translocator complex  
 G?? Inhibition of AIP-AHR binding leading to reduced AHR signaling  Nakata et al. 2009 
Hsc70 Preferential binding of Hsc70 than HSP90 in the absence of  AHR Yano et al. 2003 
  
There is currently no definitive correlation between dioxin exposure and pituitary tumorigenesis. A 
population-based study on pituitary adenoma incidence was conducted on subjects exposed to dioxin 
following an industrial accident in 1976 in Italy. However, no statistically significant increase in 
pituitary tumor incidence was noted in the contaminated area, although a tendency towards a higher 
risk was seen in subjects exposed to high to intermediate dioxin concentrations in comparison with the 
unexposed population (Pesatori et al. 2008). 
Interestingly, AHR has been shown to inhibit cell cycle progression in dioxin-induced rat hepatoma 
cells by directly inducing the cell cycle inhibitor p27Kip1 at the mRNA level, while germline mutations 
in CDKN1B encoding p27Kip1 cause MEN4 syndrome with pituitary adenomas (Kolluri et al. 1999,  
Pellegata et al. 2006, see section 4.2.2). Another mechanism by which AHR has anti-proliferative 
potential is through the direct interaction with RB1, a negative regulator of the cell cycle G1/S 
transition.  It  has  been  shown  that  in  the  presence  of  mitogenic  signals,  AHR  binds  RB1  and  co-
operates in repressing the transcription of target genes involved in G1/S transition (Puga et al. 2000). 
Loss  of  the  Rb1 chromosomal region appears to be related to aggressive pituitary tumor behavior 
(Donangelo et al. 2005). Finally, a recent study reported that Ahr functions in vivo as  a  tumor  
suppressor gene in murine liver carcinogenesis, and that its silencing may be involved in cancer 
progression (Fan et al. 2010).  
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Figure  3.  AIP-related  pathways.  AIP  resides  in  the  cytoplasm  complexed  with  AHR,  a  dimer  of  
HSP90 and p23. Ligands (e.g. dioxin) can induce translocation of AHR to the nucleus where it 
dimerizes with ARNT and regulates the transcription of genes involved in the dioxin response and in 
modulation of estrogen receptor (ER) pathways. ARNT2 can also affect ER signaling, although it is 
not known whether this involves heterodimerization with AHR. Hypoxia leads to heterodimerization 
of ARNT and HIF1? and the transcription of genes involved in the hypoxia response. Alternatively, 
ARNT2 can bind HIF1? and induce the hypoxia response (see Discussion 3.1 and 3.2). 
 
5.2.2 AIP in the regulation of cAMP 
An altered cAMP-PKA pathway is known to be involved in somatotroph tumorigenesis via the gsp 
oncogene (somatic GNAS mutations in somatotroph adenomas; MAS) or PRKAR1A mutations (CNC) 
and it is also upregulated in sporadic somatotropinomas (Spada et al. 1998, Boikos & Stratakis 2007b, 
Kirschner 2010, see sections 4.1.1 and 4.2.2). Phosphodiesterases (PDEs) degrade and deactivate 
cAMP and other cyclic nucleotides. Thus, the interaction between AIP and PDE4A5 and PDE2A is 
intriguing since it could provide a logical molecular link between somatotroph tumorigenesis and AIP 
(Bolger et al. 2003, Oesch-Bartlomowicz et al. 2005, de Oliveira et al. 2007). It has also been 
reported that cAMP activates AHR and regulates its cytoplasmic-nuclear translocation (Oesch-
Bartlomowicz et al. 2005). AIP binding to the cAMP-specific PDE4A5 inhibits its enzyme activity 
and attenuates the ability of cAMP-dependent protein kinase to phosphorylate PDE4A5. In addition, it 
was recently shown that mutant AIP loses the ability to bind PDE4A5 (Bolger et al. 2003, Leontiou et 
al. 2008). PDE2A binding to AIP has been shown to inhibit cAMP-induced nuclear translocation of 
AHR (de Oliveira et al. 2007). It was suggested that AIP-PDE2A binding may result in retention of 
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the AHR complex in the cytoplasm as a result of lower cAMP levels (Oesch-Bartlomowicz et al. 
2005, de Oliveira et al. 2007). It is currently not known what role PDE4A5, PDE2A, possibly other 
PDEs and cAMP play in AIP-mediated pituitary tumorigenesis. 
5.2.3 Interaction of AIP with RET and survivin  
Survivin belongs to the family of inhibitors of apoptosis, but it also has implications in cell division, 
chromosomal segregation, mitotic spindle formation and cellular stress responses. AIP has been found 
to be an interaction partner of survivin and it has been shown that knockdown of AIP by small 
interfering ribonucleic acid (siRNA) or competition of the survivin-AIP complex by peptidyl mimicry 
destabilizes survivin levels in cells. This enhances apoptosis but causes no changes in cell cycle 
progression. Thus, AIP regulates survivin stability and elevates the anti-apoptotic threshold of cells 
(Kang & Altieri 2006).  
There are implications that the RET proto-oncogene is also involved in survivin-AIP interactions. 
RET is a receptor tyrosine kinase for glial cell line-derived neurotrophic factor (GDNF). Gain-of-
function germline mutations of RET lead to multiple endocrine neoplasia type 2A or 2B (MEN2A or 
MEN2B) or medullary thyroid carcinoma, whereas loss-of-function mutations of RET are associated 
with Hirschsprung’s disease. RET promotes cell survival in the presence of GDNF, but induces 
apoptosis in the absence of its ligand. RET also stimulates the expression of pituitary transcription 
factor-1 (Pit-1) and p53, and induces apoptosis in somatotrophs and potentially restrains somatotroph 
proliferation (Canibano et al. 2007).  
AIP was recently identified as a novel interaction partner of RET (Vargiolu et al. 2009). The pro-
apoptotic domain of RET interacts with AIP and this interaction prevents the AIP-survivin complex 
formation.  Therefore,  in  the  presence  of  RET,  AIP  is  unable  to  bind  and  protect  survivin  from  
degradation and from a consequent increase in apoptosis. In this study, none of the pathogenic AIP or 
RET mutations analyzed disrupted the AIP-RET interaction, however, the relevance of these 
interactions in pituitary tumorigenesis remains to be elucidated (Vargiolu et al. 2009).   
5.2.4 Other cellular interactions of AIP  
AIP was first identified as the partner of viral protein hepatitis B virus (HBV) X antigen. It has been 
suggested that the X viral gene product can contribute to HBV-induced tumorigenesis. The X protein 
is also capable of inducing transformation of NIH3T3 cells and mouse hepatocytes (Kuzhandaivelu et 
al. 1996, Meyer et al. 1998). Another viral protein that binds AIP is Epstein-Barr virus encoded 
nuclear antigen-3 (EBNA-3), which plays a role in the effect of the Epstein-Barr virus on cell 
transformation (Kashuba et al. 2000, Krauer et al. 2004). The binding of AIP to the transforming 
proteins of the two viruses might indicate the involvement of AIP pathways in virus-induced cell 
transformation.  
In addition to AHR, other nuclear receptors capable of binding AIP are peroxisome proliferation-
activated receptor ? (PPAR?) and thyroid hormone receptor beta 1 (TR?1). Also the glucocorticoid 
receptor (GR) can bind AIP indirectly through HSP90 (Sumanasekera et al. 2003, Froidevaux et al. 
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2006, Laenger et al. 2009). PPAR? has roles in lipid metabolism and homeostasis. In vitro binding 
assays have revealed that cells co-expressing PPAR? and AIP have a reduced peroxisome proliferator 
response, suggesting a repressor effect of the PPAR?-HSP90-AIP complex on PPAR? activity 
(Sumanasekera et al. 2003, Yang et al. 2008). TR?1 and TR?2 are central feedback regulators of the 
hypothalamic-hypophyseal-thyroid axis and of thyroid hormone homeostasis, with TR?1 having a 
more important activating role in TRH transcription. The TPR domain of AIP has been reported to 
interact with TR?1. In a siRNA assay, knockdown of AIP resulted in the abrogation of TR?1-
mediated activation of hypothalamic transcription of TRH (Froidevaux et al. 2006). However, patients 
with AIP mutations have not been reported to have specific thyroid axis abnormalities. In addition, a 
recent study revealed that AIP can bind the HSP90-GR complex, delay its nuclear entry and inhibit 
the transcriptional activity of GR (Laenger et al. 2009).  
AIP has also been reported to interact with the translocase of the outer membrane of mitochondria 20 
(TOMM20), which is part of a translocator complex that imports mitochondrial preproteins into 
mitochondria. In vitro import assays showed that AIP maintains the import competency of the 
translocator complex (Yano et al. 2003). Another interaction of AIP has been shown to occur with G 
protein subtype 13 (G13), and the AIP-G13 interaction was able to inhibit the binding of AIP to AHR, 
leading to reduced AHR signaling (Nakata et al. 2009). In addition to binding HSP90, AIP can also 
bind another heat-shock protein, the heat-shock cognate protein 70 (Hsc70), which belongs to the 
HSP70 family. It seems that AIP preferentially forms a complex with Hsc70 rather than HSP90 in the 
absence of AHR (Yano et al. 2003, Chahal et al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Aims of the Study 
 
The primary goal  of  this  work was to clarify the molecular  and clinical  characteristics  of  PAP. The 
specific aims of studies I-V were as follows: 
 
I  To identify large genomic AIP deletions in apparently AIP mutation negative familial 
pituitary adenoma patients 
 
II To elucidate the expression of AIP-related molecules in AIP mutation positive and 
negative tumors to clarify molecular mechanisms of AIP-mediated tumorigenesis 
 
III To create a mouse model of the disease phenotype of PAP patients and to examine 
AIP-mediated tumorigenesis in vivo in the Aip mouse  
 
IV To study the clinical characteristics and response to therapy of PAP patients compared 
with sporadic pituitary adenoma patients 
 
V To evaluate the possible role of RET in familial pituitary tumorigenesis of AIP 
mutation negative pituitary adenoma patients  
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Subjects and Methods 
1. Subjects (I, II, IV, V) 
1.1 Familial pituitary adenoma patients 
In study I, the probands from 21 families with pituitary adenomas from the United Kingdom (n=8), 
Italy (n=7), Finland (n=4), Germany (n=1) and Turkey (n=1) were analyzed with the multiplex 
ligation-dependent probe amplification (MLPA) assay. All patients had previously tested negative for 
germline AIP and MEN1 mutations by conventional sequencing (Georgitsi et al. 2007a, Georgitsi et 
al. 2008, unpublished data). The tumors of index cases secreted GH (n=10) or PRL (n=4). Seven 
tumors were NFPAs. In addition, 32 sporadic Finnish GH-secreting adenoma cases aged 40 years or 
less at diagnosis and 35 sporadic Italian pediatric pituitary adenoma patients were analyzed (Table 5).  
Study IV involved 96 AIPmut+ patients without MEN1, MEN4 or CNC from 36 medical centers in 
Belgium,  Finland,  France,  Italy,  Spain,  Germany,  Bulgaria,  the  Netherlands,  Brazil,  Argentina,  the  
United States, Australia, New Zealand and Lebanon. The patients were originally diagnosed with 
pituitary adenomas in 1970-2009, and AIP mutations were found in 2006-2009. Previous studies have 
reported that AIP mutations are predominantly associated with somatotropinomas (Vierimaa et al. 
2006, Daly et al. 2007b, Georgitsi et al. 2008, Leontiou et al. 2008, Cazabat et al. 2009). A suitable 
control population was obtained from databases of collaborating study centers and comprised 232 
AIPmut-, non-MEN1, non-CNC acromegaly patients. The control group was randomly extracted to 
match the AIPmut+ group in terms of decade of diagnosis and geographic region to give ?3 control 
cases for each AIPmut+ case (Table 5).  
In study V, 16 patients from AIPmut- families with pituitary adenomas were included in the screening 
of RET mutations.  Twelve  of  these  families  were  the  same  as  in  study  I,  and  all  the  patients  had  
previously tested negative for AIP mutations (Vierimaa et  al. 2006, Georgitsi et al. 2007a, 
unpublished data). The patients were from the United Kingdom (n=6), Italy (n=5), Finland (n=3), 
Turkey (n=1) and New Zealand (n=1). The tumors secreted GH (n=8), PRL (n=3) or ACTH (n=1). 
Four adenomas were NFPAs. DNA samples from family members, if available, were analyzed when 
segregation of RET variants was evaluated (Table 5). 
1.2 Assessing patient characteristics of PAP  
In study IV, anonymized patient information on demographics, diagnosis, genetics, hormonal profiles 
at diagnosis and radiological criteria was collected. Therapeutic responses for each patient following 
neurosurgery, SSA therapy, radiotherapy, dopamine agonists and pegvisomant were collected. Long-
term responses to therapy (?12 months post-treatment) included information on hormonal, clinical 
and radiological disease status, treatment modalities used and the presence of hypopituitarism. Tumor 
size  was  measured  as  the  maximum  diameter  on  CT  or  MRI  imaging  and  tumors  were  classified  
accordingly as microadenomas (<10mm), macroadenomas (?10mm) or giant adenomas (?40mm). 
Information, if available, on extrasellar extension and invasion into surrounding structures was also 
collected from radiological reports or from surgical notes. Long-term disease control criteria (?12 
months of follow-up post-therapy) were defined according to tumor type. In all cases tumor size had 
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to be stable without growth or expansion. For patients with somatotropinoma, disease control at last 
follow-up was defined as the absence of clinical activity, an age/sex appropriate IGF-I and a valid 
random GH level  <1ng/ml.  In prolactinoma,  serum PRL had to be age/sex appropriate.  For  NFPAs,  
disease control was defined as long-term tumor size stability. In thyrotropinoma, patients had to be 
symptom-free and have normal serum TSH, T4 and T3 levels. 
Pre-defined comparison between the AIPmut+ and the control group was performed on the following 
disease and treatment characteristics: gender ratio, age at diagnosis and at first symptoms, tumor size 
and classification, proportion of patients with extrasellar extension and invasion, GH and IGF-I levels 
at baseline, PRL co-secretion at baseline, treatment characteristics (number/type of surgery, use of 
radiotherapy, hormonal and radiological responses to medical therapies), proportion of patients with 
controlled and active disease, disease control as a function of cumulative therapies, and frequency of 
hypopituitarism among patients with controlled and active disease. 
 
Table 5. AIPmut+ and AIPmut- patients and tumors. 
Study Patients/tumors analyzed Study Patients/tumors analyzed 
Study I 88 patients Study IV 96 AIPmut+ patients 
 
        48 GH-secreting tumors 
 
        75 GH-secreting tumors 
 
        23 prolactinomas 
 
        13 prolactinomas 
 
        14 NFPA 
 
        7 NFPA 
 
        3 ACTH-secreting tumors 
 
        1 TSH-secreting tumor 
Study II 14 AIPmut+ tumors 
 
232 AIPmut- GH-secreting adenoma patients 
 
        11 GH-secreting tumors Study V 16 AIPmut- patients 
 
        3 prolactinomas 
 
        8 GH-secreting tumors 
 
53 AIPmut- tumors 
 
        3 prolactinomas 
 
        35 GH-secreting tumors 
 
        4 NFPA 
 
        7 prolactinomas 
 
        1 ACTH-secreting tumor 
 
        10 NFPA 
 
7 AIPmut+ GH-secreting tumors 
          1 ACTH-secreting tumor   10 AIPmut- GH-secreting tumors 
GH-secreting tumors include mixed adenomas with GH secretion 
 
1.3 Human pituitary adenoma samples 
In study II, 67 formalin-fixed, paraffin-embedded blocks from pituitary adenoma tissue were analyzed 
for immunohistochemical (IHC) expression of AIP-related proteins. Fourteen of the samples were 
from AIPmut+ patients harboring four different mutations (Q14X, 824insA, IVS3-1G>A and IVS2-
1G>C). These adenomas secreted GH (n=5), PRL (n=3), and GH+PRL (n=6). The 53 AIPmut- 
sporadic adenomas secreted GH (n=19), PRL (n=7), GH+PRL (n=14), ACTH (n=1), 
GH+PRL+ACTH (n=1) and GH+PRL+LH+TSH (n=1). Ten adenomas were hormonally silent. 
Patients were from Finland (n=65) and the United States (n=2) (Table 5). 
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In study V, RET IHC was performed on paraffin-embedded blocks from pituitary adenoma tissue 
from seven AIPmut+ somatotropinoma patients and ten AIPmut- somatotropinoma patients. The 
tissue sections were in part from the same patients as in study II (Table 5). 
1.4 Healthy controls 
In study I, DNA from seven healthy, anonymous blood donors was used as a negative control for 
MLPA experiments. In addition, healthy, unrelated individuals from the United Kingdom (n=74), 
Germany (n=18) and the Centre d’Étude du Polymorphisme Humain (CEPH) (n=4) were used as 
controls for the mutation validation experiments.  
In study V, control samples included 279 UK Caucasians (Human Random Control DNA panels, 
Sigma-Aldrich, Porton Down, Salisbury, Wiltshire, United Kingdom) and 41 samples from Italy. 
2. MLPA assay and validation of results (I) 
Gene dosage analysis was carried out using the SALSA MLPA kit P244 designed to detect deletions 
or amplifications in AIP and MEN1 genes (MRC-Holland, Amsterdam, the Netherlands). The 
polymerase chain reaction (PCR) products were run on an ABI3730 DNA sequencer (Applied 
Biosystems, Foster City, CA, USA). Initially, electropherograms were visualized with GeneMarker 
software v.1.4 (Softgenetics LLC, State College, PA, USA). The data were exported using Peak 
Scanner software v.1.0 (Applied Biosystems). Final gene dosage analysis was performed with 
Coffalyser v.6.0 (MRC-Holland). Probes with a dosage quotient DQ of less than 0.65-0.7 (for 
deletions) or higher than 1.3- 1.35 (for amplifications) were examined for consistency by repeated 
testing. Negative controls (no DNA) were included throughout the MLPA experiments. 
Deletions detected by MLPA were confirmed by long range PCR. Fragments were amplified from 
genomic DNA by Phusion DNA Polymerase (Finnzymes, Espoo, Finland) or from complementary 
deoxyribonucleic acid (cDNA) by AmpliTaq Gold (Applied Biosystems). PCR products 
corresponding to aberrant alleles were extracted either from 1% low-melt agarose gel (Bio-Rad 
Laboratories,  Hercules,  CA,  USA)  or  1%  SeaKem  LE  Agarose  gel  (Lonza,  Rockland,  ME,  USA)  
using the QIAquick Gel Extraction Kit (Qiagen GmbH, Hilden, Germany), and sequenced using 
BigDye 3.1 termination chemistry on an ABI3730 DNA sequencer (Applied Biosystems). 
The whole genomic region of AIP and 2 kilobases (kb) upstream of the 5’ untranslated region (UTR) 
(NCBI36:11:67,005,097:67,015,750 and Ensembl release 48) was scanned for possible Alu repeats 
using GEMS Launcher – ModelInspector software (release 5.4.3, May 2007) (Genomatix Software 
GmbH, Munich, Germany) and the Repeat Masker program (v.3.1.9). Sequence identities of Alu 
repeats were evaluated by NCBI BLAST 2 Sequences (BLASTN, v.2.2.17). 
3. Immunohistochemistry of pituitary adenomas (II, III, V) 
In studies II, III and V, IHC was performed according to standard procedures on 4-5 µm sections of 
paraffin-embedded pituitary adenoma specimens, followed by anonymous evaluation by a pathologist. 
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The Power Vision rabbit or rabbit/mouse Poly-HRP IHC Kit (ImmunoVision Technologies, Norwell, 
MA,  USA),  Dako  ENVISION  Kit  (Dako,  Glostrup,  Denmark),  or  PowerVision  Poly-HRP  IHC  
Detection System kit (PV6104; Leica Biosystems Newcastle Ltd, Newcastle, United Kingdom) was 
used for antibody detection. 3,3’-diaminodenzidine (DAB) was used as a chromogen and 
haematoxylin as a counterstain.  
In study II, the stained proteins were ARNT (SC-5580; 1:200; Santa Cruz, CA, USA), AHR (ab2770; 
1:2000; Abcam, Cambridge, United Kingdom) HIF1-? (610958; 1:100; BD Biosciences, San Jose, 
CA, USA), p27Kip1 (610244; 1:500; BD Biosciences) and cluster of differentiation 34 (CD34) 
(M7165; 1:50; Dako). AHR staining was scored as negative (0) or positive (1). The staining intensity 
of ARNT, HIF1-?, and p27Kip1 was scaled as negative (0), weak (1), intermediate (2), or high (3). In 
addition, the fraction of the positively staining cells was evaluated in the case of HIF1-?. Specimens 
with less than 1% of staining cells were scored as 0, 1-10% of positive cells as 1, 10-50% of positive 
cells as 2, and more than 50% of positive cells as 3. The density of CD34-vessels per square 
millimeter was recorded. To avoid imprecision, the mean of two separate vessel counts was calculated 
in most samples. 
In study III, the hormonal status of the mouse pituitary adenomas was assessed by GH (A0570; 1:400; 
Dako), PRL (A0569; 1:4000; Dako) and ACTH (PA1-36035; 1:2000; AH diagnostics, Århus, 
Denmark) IHC. In addition, expression of AIP (ab48833; 1:100; Abcam), ARNT (ab14829; 1:50; 
Abcam), ARNT2 (sc5581/clone M-165; 1:100; Santa Cruz), HIF1-? (NB100-479; 1:200; Novus 
Biologicals, Littleton, CO, USA), estrogen receptor ? (ER?) (ab80922; 1:100; Abcam) and the Ki-67 
proliferation marker (ab15580; 1:250; Abcam) was investigated. The AIP protein and the hormone 
IHCs were scored either as negative or positive. The staining intensity of ARNT, ARNT2 and HIF1-? 
was scaled as negative (0), weak (1), intermediate (2), or high (3). In the case of macroadenomas, the 
Ki-67 proliferation index (PI=the number of Ki-67 positive cells among the total number of resting 
cells) was evaluated from 100-500 tumor cells in the area of strongest expression. If the pituitary 
tumor contained less than 100 cells, all the cells were counted. Only distinctly stained nuclei were 
considered as immunopositive. ER? intensity was scaled as negative (0), weak (1), intermediate (2), 
or high (3). The percentage of ER? positive cells was evaluated on a scale of 0 to 4 (0%=0, 1-25%=1, 
26- 50%=2, 51-75%=3, and >75%=4). Finally, the Q-score method (intensity score + % cells stained, 
range 0-7) was used to quantify ER? expression (Lee et al. 2002). 
In study V, RET (ab51122; 1:75; Abcam) expression was scored as negative (-) or positive (+). In 
cases where the tumor stained partly negative and partly positive, the tumor was scored as (+/-). 
4. Cell culture studies (II) 
4.1 Aip silencing and cell proliferation assay 
Human embryonic kidney (HEK293) cells, HeLa cells, rat mammosomatotroph GH3 cells and Aip-
null, heterozygote (HET) and wildtype (WT) mouse embryonic fibroblasts (MEFs) from embryonic 
day (E) 12.5 mouse embryos were cultured in 95% air, 5% CO2 at  37°C.  HEK293  and  HeLa  cells  
were transfected with 30nM duplex siRNA strands of AIP siRNA or non-targeting control siRNA 
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containing a pool of four different oligos (Dharmacon, Lafayette, CO, USA) using Dharma FECT™1 
transfection reagents (Dharmacon). GH3 cells were electroporated using AmaxaTM nucleofector 
(Amaxa Biosystems, Gaithersburg, MD, USA) with 100nM siRNA oligos (Dharmacon). In all studied 
cell lines, RNA was extracted with the RNeasy Mini Kit (Qiagen), cDNA was produced by standard 
methods and the relative expression levels of AIP/Aip were determined using TaqMan chemistry and 
the 7500 Fast Real-Time PCR system (Applied Biosystems). AIP/Aip TaqMan probes for human, 
mouse, and rat transcripts were Hs00610222_m1, Mm00479316_m1, and Rn00597273_m1 (Applied 
Biosystems), respectively. The relative mRNA copy numbers were normalized against the ?-actin 
housekeeping gene (4326315E for human, 4352341E for mouse, and 4352340E for rat transcripts; 
Applied Biosystems). The proliferative status of AIP/Aip siRNA transfected and non-treated HEK293, 
HeLa  and  GH3  cells  was  determined  by  the  MTS  assay  (G3580;  Promega,  Madison,  WI,  USA).  
Conversion of MTS into formazan was detected at the absorbance of 490nm according to the 
manufacturer’s instructions (Promega). Measurement time points for HEK293 and HeLa cells were 
from 20h until 72h, and for GH3 the timescale was from 6h until 72h. 
4.2 Western blot analyses 
Proteins from MEFs, HEK293, HeLa and GH3 cells were extracted with M-PER Mammalian Protein 
Extraction  Reagent  (Pierce,  Rockford,  IL)  or  RIPA buffer  (Sigma-Aldrich,  Saint  Louis,  MO,  USA)  
supplemented with proteinase inhibitor (Roche, Mannheim, Germany). Twenty-five ?g of protein was 
loaded into a 10% Tris-HCL gel (Bio-Rad Laboratories). Primary antibodies against AIP (NB100-
127; 1:1000 in MEFs and 1:500 in HEK293, HeLa, and GH3 cells; Novus Biologicals) and ARNT 
(ab14829; 1:200; Abcam) were used. ?-Tubulin (T5168; 1:5000; Sigma-Aldrich) was used as a 
loading control protein. Proteins were visualized using the Amersham™ ECL Plus Western Blotting 
Detection System (GE Healthcare, Buckinghamshire, United Kingdom). Western blot band intensities 
were calculated with FluorChem™ 8800 using the Spot Denso analysis tool (Alpha Innotech 
Corporation, San Leandro, CA, USA). The program calculates integrated density values for the bands 
based on band areas and intensities. ARNT band values were normalized against band values from ?-
Tubulin of the same sample. Band intensity was reported as a percentage relative to the control siRNA 
band. 
5. Statistical analysis (II, III, IV, V) 
In studies  II,  III  and V,  Fisher’s  exact  test  or  the Fisher  Freeman-Halton extension test  was used to 
test statistical significances. 
In study III, the chi-square (?2) -statistic was used to investigate the deviation of genotypes of live Aip 
embryos from the expected Mendelian 1:2:1 ratio. Comparisons between the groups were drawn 
through the parametric Student’s t-test, and in cases of non-normally distributed variables the non-
parametric Wilcoxon-Mann-Whitney U test was applied. Correlations were assessed by Spearman 
rank correlation. 
In study IV, continuous data were represented as medians and ranges. For non-normally distributed 
data, comparisons were made using a non-parametric test, Wilcoxon’s signed-rank test. For count 
data, values were placed in a contingency table and compared with a chi-square test. Where 
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continuous data were plotted as density graphs, a kernel density approximation was computed using a 
Gaussian kernel and bandwidth calculated using Silverman’s “rule of thumb”. The kernel density was 
finally plotted as a continuous curve. 
6. The Aip mouse model (III) 
6.1 Generation of Aip mutant mice 
Embryonic stem cells (ES cells) containing the gene trap vector construct in an intronic region of 
genomic DNA between Aip exons 2 and 3 (ENSMUST00000117831) (BayGenomics, University of 
California, Davis, CA) were injected into blastocysts, and chimeras were then identified (Stanford et 
al. 2001). The inbred mouse strain C57BL/6Rcc was used for generation of congenic mice. Mice were 
genotyped as Aip HET or WT by a multiplex PCR reaction from cDNA or genomic DNA, amplifying 
the WT and mutant alleles (Figure 4). Total RNA or DNA was extracted from the ear using the 
RNeasy Mini Kit (Qiagen) or the DNeasy Blood & Tissue Kit (Qiagen) and cDNA was produced 
according to standard protocols.  
6.2 Collection and staining of tissues 
HET and WT mice were followed up in a cohort study in which necropsies were performed at three-
month intervals, from 3 to 21 months of age. Mice used in the study had 89-100% C57BL/6Rcc 
genetic background. Analysis in each age group included HET mice and age-matched WT controls 
from the same litters with both genders represented close to 1:1. Following CO2 anesthesia and neck 
dislocation, the pituitary, thyroid/parathyroid, adrenal glands, pancreas, brain, kidneys and liver were 
dissected. Other tissues were also collected if macroscopic abnormalities were detected. The total 
weight of the mice and the relative weights of their liver, spleen, and kidneys (organ weight/total 
weight of mouse x 100) were measured. Small tissues were fixed up to two hours and larger ones 
overnight in cold 4% paraformaldehyde. The pituitary was retained on top of the skull and fixed for 
1.5 hours followed by decalsification of two hours. Fixed tissues were embedded in paraffin and 
sectioned at 5?m. Haematoxylin-Eosin (HE) staining of the pituitary was performed approximately in 
every 50?m to thoroughly analyze the histopathological features. From other tissues, all macroscopic 
abnormalities were further examined at the microscopic level. 
6.3 LOH analysis 
To  assess  the  presence  of  LOH,  fresh  pituitary  tumor  DNA  from  two  heterozygote  mice  was  
sequenced. Multiplex PCR was performed with one forward primer targeted in the WT sequence, 
another forward primer in the insertion and a reverse primer in the WT sequence. Allelic imbalance 
was scored by comparing the ratios of the allele peak heights between normal and tumor samples as 
described previously. The cutoffs for LOH were <0.60 and >1.67 (Canzian et al. 1996, Pastinen et al. 
2004). 
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Figure 4. Aip mouse construct and genotyping. Genomic Aip sequence and gene trap vector construct 
inserted in IVS2. The gray triangle indicates the splice acceptor site after mouse En2 intron 1 
sequence. The B-geo fusion gene contains ?-galactosidase and neomycin, and pA is a polyadenylation 
signal. Blue arrows designate genomic primers and red arrows designate cDNA primers used in 
genotyping PCR. Gel pictures show results of genomic and cDNA genotyping with wildtype (wt) and 
mutant (mut) bands. 
 
6.4 Igf-1 expression analysis 
RNA was extracted from the liver of 18-month-old HET and WT mice with the RNeasy Mini Kit 
(Qiagen) and cDNA was produced by standard methods. The relative expression of Igf-1 was 
determined using TaqMan chemistry and the 7500 Fast Real-Time PCR system (Applied Biosystems). 
The Igf-1 probe was Mm00439560 (Applied Biosystems) and the relative mRNA copy numbers were 
normalized against the ?-actin housekeeping gene (4352341E; Applied Biosystems). 
7. RET sequencing and Enhancer Element Locator (EEL) analysis (V) 
RET mutation screening was performed on genomic DNA. PCR products were purified using the 
ExoSAP-IT PCR purification kit (USB Corporation, Cleveland, OH, USA). DNA sequencing was 
performed using BigDye 3.1 termination chemistry on an ABI3730 DNA sequencer (Applied 
Biosystems). The whole coding region of RET (Ensembl version 55 gene ENSG00000165731, 
transcript ENST00000340058) and flanking intronic sequences of exons were sequenced, as well as 
5’UTRs and 3’UTRs, promoter regions and a non-coding RET variant (rs2435357). Evaluation of 
sequences was done with Mutation Surveyor software v.3.24 (SoftGenetics). 
EEL is a computational tool that predicts enhancer elements based on e.g. analysis of transcription 
factor binding affinity (Hallikas et al. 2006). Genomic human and mouse sequences 50 kb up- and 
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downstream from RET and Ret (GRCh37:10:43522517:43675799:1 and 
NCBIM37:6:118051766:118197762:1, respectively) were aligned and the EEL computer algorithms 
were applied as previously described to detect possible enhancer elements in and around RET (Palin et 
al. 2006); 149 previously described transcription factor binding site matrices were used (Hallikas et 
al. 2006, Badis et al. 2009, Jaspar2). 
8. Ethical issues (I, II, III, IV, V) 
Studies I, II and V were approved by the Ministry of Social Affairs and Health and the Ethics Review 
Committees of the hospital district of Helsinki and Uusimaa. 
Permission to use the patient samples (studies I, II and V) was obtained either by appropriate 
informed consent of patients or by the permission of the National Authority for Medicolegal Affairs. 
All the animal experiments were authorized by the appropriate review committee (National Animal 
Experiment Board) and regulations concerning the use of animals in research were adhered to in study 
III. 
In study IV, all patients provided informed written consent for genetic testing at their medical center, 
and the study was approved by the Ethics Committee of the Centre Hospitalier Universitaire de Liège. 
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Results 
1. Identification of large genomic deletions in AIP (I) 
Two out of 21 (9.5%) AIP and MEN1 mutation negative families were found to harbor one distinct 
deletion each. Copy number changes were not detected either among 32 sporadic Finnish GH-
secreting adenoma cases or in 35 Italian pediatric pituitary adenoma patients. 
1.1 Exon 2 deletion 
A heterozygous AIP exon 2 deletion (Ex2del) was found in a British family where the index case had 
NFPA and his brother had a GH-secreting adenoma. Also, a maternal second cousin had been 
diagnosed with NFPA, but no clinical data or tumor sample was available. The Ex2del results in the 
in-frame ablation of 60 amino acids (A34_K93del), which corresponds to three-quarters of the 
FKBP12-like domain (Meyer et al. 1998). Sequencing of the aberrant allele revealed Ex2del as part of 
a larger deleted fragment of 1562 basepairs (bp). The deletion was absent in 74 healthy population-
matched controls. To examine whether Ex2del occurs due to an Alu-mediated recombination 
mechanism, in silico search of the chromosome 11 region 67,005,097- 67,015,750 was performed. 
Interestingly, it revealed the presence of eight Alu repetitive elements: four were located upstream of 
the 5’UTR, and four spanned exon 2. Both breakpoints of the deleted fragment occurred within Alu 
repeats, resulting in the retention of the IVS1 Alu repeat in the mutant allele, whereas the most part of 
the IVS2 Alu was lost (Figure 5, see Discussion 1). 
 
 
 
 
Figure 5. AIP and Alu repeats.  This  is  a  schematic  illustration  of  the  5’  AIP sequence with black 
arrows indicating Alu repeats flanking exons 1, 2 and 3. Ex1_2del and Ex2del are also depicted. 
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1.2 Exon 1 and 2 deletion 
The second AIP deletion was detected in the proband of a previously reported German family with 
two acromegaly patients (Ackermann et al. 1999, Vierimaa et al. 2006). The heterozygous deletion 
encompasses AIP exons 1 and 2, including the 5’UTR (Ex1_2del). Sequencing of the aberrant allele 
revealed a deletion of 5818 bp, encompassing 1104 bp upstream of the 5’UTR and 578 bp of IVS2. 
The deletion was absent in 22 healthy Caucasian controls. The deletion breakpoints did not occur 
within Alu repeats, but in close proximity, suggesting the involvement of an Alu-mediated deletion 
(Figure 5).  
2. Elucidating the expression of AIP-related proteins in pituitary adenomas (II) 
To study the impact of AIP mutations on the expression of AIP-related proteins, IHC was performed 
on a set of AIPmut+ and AIPmut- pituitary adenomas. Since ARNT was found to be underexpressed 
in AIPmut+ adenomas, the ARNT expression was then analyzed in AIP/Aip silenced and Aip 
knockout cell lines. Last, the proliferation rates of AIP/Aip silenced cell lines were determined.  
2.1 Immunohistochemistry results 
When negative (score 0) and weak (1) intensities were considered as negative staining and 
intermediate (2) and high (3) intensities as positive staining, ARNT was found to be more frequently 
expressed in AIPmut- tumors compared with AIPmut+ tumors (p=0.001, Table 6). This association 
remained significant when also weak (1) intensity was considered positive staining (p=0.0016). No 
correlation between the expression of ARNT and the hormone secretion status of the adenoma was 
found. By contrast, the expression of ARNT in adjacent normal tissue was consistent in AIPmut+ and 
AIPmut- samples. Nuclear AHR was more frequently expressed in AIPmut+ samples compared with 
AIPmut- samples, although the result was not statistically significant (p=0.067). The cytoplasmic 
expression of AHR and the staining intensity and fraction of HIF1-? positive tumor cells were even 
between tumor types (p=0.51, p=0.09 and p=0.25, respectively). Adjacent normal pituitary tissue did 
not display HIF1-? staining. Expression of p27Kip1 was  even  between  tumor  types  (p=0.32),  and  all  
AIPmut+ tumors showed a prominent p27Kip1 expression. No statistical difference between the density 
of CD34-vessels in AIPmut+ samples (mean 319.5/mm²) compared with AIPmut- samples was 
detected (mean 253.1/mm²) (p=0.11). 
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Table 6. ARNT and ARNT2 immunohistochemistry in human and mouse pituitary adenomas. 
Protein expression AIP/Aip mut+  AIP/Aip mut-  p-value 
Human ARNT 6/13 40/44 0.001¹ 
Mouse ARNT 40/54 14/14 <0.00001¹,² 
Mouse ARNT2 14/54 14/14   
¹ Fisher’s exact test 
² loss of either ARNT or ARNT2 in Aip-deficient GH-secreting adenomas 
  
2.2 ARNT expression in cell lines 
The expression of AIP and ARNT was studied in HEK293, HeLa, GH3 and MEF cells. Quantitative 
PCR  (qPCR)  showed  lack  of  Aip transcription in Aip-null  MEFs  when compared to HET and WT 
MEFs. Western blot analysis of an Aip-null MEF line confirmed the lack of AIP protein. However, 
Aip-null and WT MEF cells showed no differences in the amounts of ARNT in western blot analysis. 
AIP siRNAs reduced the expression of AIP/Aip in  HEK293,  HeLa  and  GH3  cell  lines  by  
approximately 85%, 90%, and 25-87%, respectively. Western blot analysis showed a notable 
reduction of AIP protein in AIP siRNA treated HEK293 and HeLa cells at 48h, but equal presence of 
ARNT when compared with control siRNA-treated cells. Instead, pituitary adenoma cell line GH3 
showed notable reduction of ARNT after Aip siRNA transfection by electroporation (with 60% 
transfection efficiency). At a 6h time point, the ARNT band intensity of Aip siRNA-treated cells was 
51.6% in contrast to the ARNT band intensity of control siRNA transfected cells. At a 48h time point 
with 59% transfection efficiency, no reduction of ARNT was observed.  
2.3 Cell proliferation 
To evaluate the possible effect of AIP/Aip silencing on cell proliferation, AIP/Aip siRNA-treated 
HEK293,  HeLa  and  GH3  cells  were  analyzed  with  the  MTS  assay.  AIP siRNA-treated HeLa cells 
showed no difference in proliferation compared with control siRNA-treated cells. HEK293 cells 
showed slightly increased proliferation 72 hours after transfection. In contrast, Aip siRNA transfection 
of GH3 cells resulted in a clearly increased rate of proliferation already at 48h (Figure 6). 
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 Figure 6. MTS assay shows increased cell proliferation in GH3 cells after Aip knockdown with 
siRNA, compared with control siRNA and untreated cells.  
 
3. Creating Aip mutant mice prone to pituitary adenomas (III) 
The Aip mutation was generated by inserting a gene trap vector construct into an intronic region of 
genomic DNA between Aip exons 2 and 3 (ENSMUST00000117831) (BayGenomics, University of 
California, Davis, CA) (Stanford et al. 2001, Figure 4). The inserted vector construct created an 
artificial splicing site after 34 codons (34/331). No leakage of the construct was observed when tested 
by qPCR and western blotting (see study II). The crossings of heterozygous mice yielded one live 
Aip-null, 37 HET, and 22 WT embryos when analyzed at E12.5 stage. This deviates significantly from 
the expected Mendelian 1:2:1 ratio (?2=17.97, p<0.001). No living Aip-null pups were born. 
3.1 Phenotype and tumor spectrum of Aip mice 
Viability or total weight did not differ between WT and HET mice. The relative weights of the liver, 
kidneys,  and  spleen  were  the  same  between  HET  mice  and  their  WT  littermates  up  to  12  months.  
However, a trend towards increased relative organ weights of ?15-month-old HET mice was seen 
compared to WT mice. Observation of 21 months did not reveal excess of any other tumor type than 
pituitary  adenomas  in  HET  mice  compared  with  WT  littermates.  AIP  IHC  for  tumors  of  the  lung  
(n=1), liver (n=5) and kidney (n=2) from HET mice was performed, but all showed AIP expression, 
suggesting that AIP was not associated with the formation of these tumors. A slight excess of 
macroscopically visible hyperplasia of adrenal glands was detected in HET mice compared with WT 
mice (p=0.16). Histopathological examination, however, did not reveal any neoplastic growth. 
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Altogether 88 HET and 58 WT mice were examined. Of HET mice, 69 out of 88 (78.4%) developed 
one or more pituitary tumors, while only 12 out of 58 WT mice (20.7%) displayed this tumor type 
(p<10-6). HET mice showed the first pituitary lesions at six months of age. Several macroscopically 
visible macroadenomas were detected among HET mice in older age groups. The pituitary tumor 
phenotype reached full  penetrance in HET mice at  the age of  15 months and it  was not  affected by 
variable purity of genetic background (89-100% C57BL/6Rcc). No differences in pituitary adenoma 
formation between sexes was detected (p=0.21). HET mice were prone to developing multiple 
primary pituitary tumors already at the age of six months, whereas multifocal pituitary tumors were 
detected among the WT mice at much older age groups (15-21 months). The majority of HET mice 
developed GH-secreting adenomas (61/69, 88%) (Figure 7). The remaining HET tumors were mostly 
prolactinomas, but also two mixed GH+PRL adenomas and one ACTH-secreting tumor were seen. 
The majority of the adenomas in WT mice were prolactinomas (25/27, 92.6%). Also two GH+PRL 
tumors were detected (7.4%). WT mice did not develop purely GH-secreting adenomas. 
3.2 Loss of Aip in pituitary tumors 
LOH was assessed from fresh tumor tissue of  two Aip HET mice.  The cutoffs  for  LOH were <0.60 
and >1.67 for mutant and WT alleles, respectively (Canzian et al. 1996). The allele peak ratios in the 
normal/tumor pairs were 2.19 and 2.08, indicating reduction of the WT allele in these tumors. 
Complete  loss  of  the  WT  allele  was  not  seen  due  to  normal  tissue  contamination.  AIP  IHC  of  all  
studied GH-secreting adenomas from HET mice revealed negative AIP immunostaining. Also the 
majority of the HET prolactinomas (22/26, 84.6%) as well as one ACTH-secreting tumor showed lack 
of AIP. Four HET prolactinomas showed positive AIP staining, suggesting that these lesions are not 
related to the Aip mutation. All WT pituitary adenomas showed positive AIP expression. 
3.3 Proliferation index of tumors 
Ki-67 IHC analysis was performed to evaluate the proliferation rate of HET and WT tumors. The Ki-
67 protein is expressed in all phases of the active cell cycle (G1, S, G2 and M phase), but is absent in 
resting (G0) cells. HET tumors had a significantly higher proliferation rate compared with WT 
adenomas (p=0.014). No correlation between age and proliferation rate was detected (Spearman rank 
correlation; rho=-0.12, p=0.59). There was no clear correlation between the hormonal status of tumors 
of HET mice and the proliferation index (PI) values (p=0.05, Student’s t-test), although Aip-deficient 
prolactinomas showed a higher average PI when compared to Aip-deficient GH-secreting tumors, 
10.1±3.6 (s.d.) vs. 6.1±4.7 (s.d.), respectively. 
3.4 Igf-1 expression in mice with Aip-deficient somatotropinomas 
GH functionality of HET somatotropinomas was assessed by measuring the expression of liver Igf-1 
by  qPCR.  Seven  HET  mice  and  11  WT  mice  were  studied.  Three  of  the  WT  mice  had  GH+PRL-
secreting adenomas. The mean Igf-1 expression for seven HET mice with somatotropinomas was 
1.9±0.26 (s.d.), and for the eight WT mice without GH-secreting adenomas 1.4±0.22 (s.d.). The 
relative Igf-1 expression value for the WT mice with GH-secreting adenomas was 1.8±0.11 (s.d.), thus 
in line with the expressions measured from the HET mice. Altogether, the HET mice had significantly 
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elevated Igf-1 expression levels compared with the WT mice that did not have GH-secreting 
adenomas (p=0.002, Student’s t-test). 
 
 
 
 
Figure 7. Immunohistochemistry of GH and AIP. (A) One GH positive and one GH negative pituitary 
adenoma in an Aip HET mouse. The GH negative tumor stained positive for PRL in subsequent PRL 
immunohistochemistry. (B) Negative AIP staining in the pituitary adenoma of an Aip HET mouse. 
Tumors are indicated by black arrows. Scale bars 200µm (A) and 100µm (B).  
 
3.5 Estrogen receptor ? expressions in Aip-deficient and -proficient tumors 
IHC was used to assess the expression of ER?. The study comprised 30 Aip-deficient adenomas (14 
PRL- and 16 GH-secreting tumors) and eight Aip-proficient prolactinomas. All Aip-proficient tumors 
and 29/30 of Aip-deficient tumors showed a distinct nuclear expression of ER?. The Aip-proficient 
tumors showed significantly higher ER? expression compared with the Aip-deficient adenomas (GH 
and PRL), mean 4.6 ±0.70 (s.d) vs. 3.8±1.37 (s.d.), respectively (p=0.02, Student’s t-test). However, 
no statistically significant difference between Aip-deficient and -proficient tumors was found when 
only prolactinomas were compared (p=0.11). ER? expression did not correlate with the proliferation 
rate or gender (rho=-0.31, p=0.65, Spearman rank correlation; p=0.34, Student t-test, respectively). 
No statistical significance between ARNT or ARNT2 deficiency and ER? expression was detected 
(p=0.37, Student’s t-test). ER? was present in all normal pituitaries and the expression was similar 
between HET and WT mice, 5.7±0.8 (s.d.) and 5.6±0.7 (s.d.), respectively. 
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3.6 ARNT/ARNT2 imbalance 
ARNT and ARNT2 IHC showed a total lack of ARNT in 14 and of ARNT2 in 40 Aip-deficient 
tumors. GH-secreting Aip-deficient tumors more often showed lack of ARNT2 than ARNT (?2=7.28, 
p<0.007, Table 6). Remarkably, almost all Aip-deficient tumors expressed only ARNT or ARNT2 
(49/53, 92.5%, p<10-5, Fisher’s exact test, Table 6). In contrast, both proteins were present in all Aip-
proficient tumors (10/10 in WT animals and 4/4 in HET mice). No difference in proliferation rates 
between Arnt-deficient (n=4) and Arnt2-deficient (n=9) tumors was detected; median 4% (range 2-
8%) vs. 4% (2-10%), respectively (p=0.73, Mann-Whitney U test). To examine the hypoxia response 
in Aip-deficient and -proficient tumors, HIF1-? IHC was performed. A total of 50 Aip-deficient and 
13 Aip-proficient tumors were studied. HIF1-? was present in 46/50 of Aip-deficient tumors and in all 
Aip-proficient samples, and staining intensity averages were 1.8±0.9 (s.d.) and 2.0±0.4 (s.d.), 
respectively (p=0.26, Student’s t-test). Aip-deficient and -proficient prolactinomas showed 
significantly higher HIF1-? expression when compared with Aip-deficient somatotropinomas 
(p=0.002). Expression of HIF1-? was found to be even between ARNT and ARNT2 negative tumors. 
(p=0.92, the Freeman-Halton extension of Fisher’s exact probability). Similarly, there was no 
correlation between HIF1-? intensity and the proliferation rate (p=0.51, Mann-Whitney U test). 
Adjacent normal pituitary tissue had weak cytoplasmic or absent HIF1-? staining. 
4. Assessing clinical characteristics of PAP (IV) 
The study population comprised 96 AIPmut+ pituitary adenoma patients with 43 separate AIP 
mutations. Most patients presented in FIPA kindreds (59.4%) and the rest had no known familial 
background of pituitary adenomas. There were no statistical differences in clinical or therapeutic 
characteristics among patients with different types of AIP mutations.  
4.1 PAP patient demographics 
The AIPmut+ population was predominantly male (63.5%) and the median age at first symptoms was 
18.0 years, indicating that half of the patients were children or adolescents at clinical onset. Tumors 
were overwhelmingly macroadenomas (93.3%) including 12 giant adenomas, and 56.3% had invaded 
local structures at diagnosis. No statistically significant differences existed between characteristics in 
AIPmut+ male and female patients. 
4.2 Characteristics of AIP mutation positive pituitary adenomas 
Somatotropinomas were diagnosed in 78.1% of AIPmut+ patients. This AIPmut+ group comprised 
mainly of males (61.3%), and there was a significantly higher male-to-female ratio than in AIPmut- 
controls (p=0.027). The median age at first symptoms was 20.5 years earlier in AIPmut+ patients vs. 
controls (p<0.000001); first symptoms occurred as children or adolescents in 52.2% of the AIPmut+ 
cohort. Similarly, the AIPmut+ cohort was diagnosed nearly two decades before AIPmut- controls 
(p<0.000001). Gigantism was more frequent in the AIPmut+ cohort (p<0.000001). All 24 patients 
with gigantism in the AIPmut+ group were males as compared with 10/15 (66.7%) male patients with 
gigantism in the control group. The median maximum tumor diameter was larger (p=0.00026) and the 
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proportion of patients with macroadenomas was higher in the AIPmut+ group (p=0.026). Giant 
adenomas were seen in 9.3% of the AIPmut+ group as compared with 1.3% among controls. There 
was a higher frequency of extrasellar extension (p=0.018) and a trend towards more frequent invasion 
of local structures in the AIPmut+ cohort versus controls. Larger tumor size in the AIPmut+ group 
was associated with significantly higher median levels of GH at diagnosis than in controls 
(p=0.00068); median IGF-I levels did not differ (p=0.48). Co-secretion of GH and PRL was nearly 
twice as frequent in the AIPmut+ group as it was in controls (p=0.00023). 
Thirteen AIPmut+ patients had prolactinomas. Most of these patients were male (76.9%). Patients had 
young median ages at first symptoms (18.0 years) and diagnosis (22.0 years) and median prolactin 
levels at diagnosis were 2520.0ng/ml; range 74.0-60,000.0ng/ml. Median maximum tumor diameter 
was large (31.0mm; range: 6.0-85.0mm), 12/13 tumors were macroadenomas and 11 of these had 
extrasellar extension and nine were invasive at the time of diagnosis. 
There were also seven patients with NFPAs in the AIPmut+ cohort. The median age at diagnosis was 
younger than commonly described for this disease (31.0; range: 12.0-74.0 years) (Ferrante et al. 
2006). All tumors were macroadenomas; six had suprasellar extension and four were invasive at 
diagnosis. Two patients presented with pituitary apoplexy. At diagnosis, all patients had mildly 
elevated prolactin levels. In addition, one patient had hypogonadism and one had hypofunction of the 
adrenal, thyroid and gonadal axes at the time of diagnosis.  
In addition, one AIPmut+ patient presented with elevated T3 and T4 levels  and a  normal  TSH level,  
and had a non-invasive pituitary macroadenoma detected by MRI. No other hormonal abnormalities 
were noted at diagnosis. 
4.3 Response to therapy  
In somatotropinomas, combinations of different treatment modalities or duration of follow-up post-
diagnosis did not differ between AIPmut+ and AIPmut- groups. Among 71 AIPmut+ 
somatotropinoma patients with >12 months of follow-up, disease control was achieved in 50 cases 
(70.4%) and acromegaly remained active in 21 cases (29.6%). The long-term disease control rate was 
higher in control patients (182/226; 80.5%) (p=0.06). Among patients with a higher cumulative 
treatment burden (?3 distinct modalities), long-term disease control rates were poorer in the AIPmut+ 
group versus controls (p=0.01). A similar proportion of patients had pituitary neurosurgery in the 
AIPmut+ and control groups; re-operation was significantly more frequent in the AIPmut+ group than 
in controls (p=0.00069). There was a trend toward more frequent use of radiotherapy in the AIPmut+ 
group than in controls (p=0.15). Percentage reduction in GH and IGF-I was similar for primary, pre- 
and post-operative SSA use in both groups. In the AIPmut+ group the median SSA-induced reduction 
in GH and IGF-I was lower than that seen in the control patients treated with SSA (p=0.0004 and 
p=0.028, respectively). The median magnitude of tumor shrinkage achieved with SSA was 
significantly higher in the control group vs. AIPmut+ patients (p<0.000001). Concomitant 
radiotherapy use was similar among patients that were controlled versus not controlled by SSA in the 
two groups. Unlike in the AIPmut+ group where three of four patients were uncontrolled by 
pegvisomant therapy, all 19 control acromegaly patients that received pegvisomant therapy had 
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controlled IGF-I levels at follow-up. The frequency of hypopituitarism was similar in the AIPmut+ 
and control groups, but the AIPmut+ group had a significantly higher number of deficient axes than 
control patients (p<0.000001). 
In AIPmut+ prolactinomas, all but one patient received primary dopamine agonist therapy, which was 
associated with reduction of 50-99% from baseline PRL. Initial normalization of PRL secretion 
occurred in five cases; one patient developed secondary dopamine agonist resistance and tumor 
growth despite high-dose cabergoline and needed two transsphenoidal surgeries plus radiotherapy to 
achieve disease control. Six patients were initially uncontrolled with dopamine agonists and 
underwent surgery, one of which underwent three transsphenoidal and one transcranial intervention 
plus radiotherapy, while another two patients had two surgical interventions each. Radiotherapy was 
eventually undertaken by three operated patients. Long-term control of PRL secretion was achieved in 
8/13 (61.5%) patients and two patients developed hypopituitarism. 
In AIPmut+ NFPAs, six patients underwent surgery and one patient who underwent a transcranial 
approach received radiotherapy due to a large remnant. Long-term control of tumor size was achieved 
in all cases. All patients had mildly elevated prolactin levels at diagnosis, and in three patients that 
received dopamine agonists, two achieved normal prolactin levels (no tumor shrinkage). At diagnosis, 
one patient had hypogonadism and one had hypofunction of the adrenal, thyroid and gonadal axes, 
which did not resolve post-therapy. 
The patient with a TSH-secreting adenoma underwent transsphenoidal surgery twice, followed by 
octreotide treatment, which resulted in hormonal normalization but no change in residual tumor size. 
5. Evaluating the role of RET in familial pituitary adenomas (V) 
Patients from 16 AIPmut- pituitary adenoma families were screened for RET germline mutations to 
assess whether RET could play a role in pituitary adenoma predisposition, similar to AIP. The RET 
region was also analyzed with EEL to identify RET regulatory elements and to see if the found RET 
changes resided in these. Finally, expression of RET was examined in AIPmut- and AIPmut+ 
somatotropinomas by IHC. 
5.1 RET heterozygous changes 
Five novel heterozygous RET variants were found when sequencing the RET region. A heterozygous 
c.785T>C (V262A) change was found in RET exon 4 in an Italian prolactinoma patient. However, this 
variant was absent in the patient’s acromegalic aunt, and the change was not found in 41 Italian 
controls. A heterozygous 3’UTR change c.1560*G>A was detected in a British prolactinoma patient 
and her sister with prolactinoma. The change was not found in an unaffected sister or in 279 British 
Caucasian controls. In the same patient we also found an unreported heterozygous IVS17+105delG. 
However, the affected sister did not share the deletion, and it was also found in the unaffected sister 
and 10 of 91 analyzed British Caucasian controls. A heterozygous -1285G>A change upstream of 
RET was found in a British NFPA patient of Vietnamese origin. It was also present in the patient’s 
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mother with NFPA. No Asian controls were available. The mother also had a heterozygous -1491C>T 
change that was not present in her child. 
5.2 EEL analysis 
The EEL tool was used to predict whether the two segregating RET variants, c.1560*G>A and -
1285G>A, could reside in putative enhancer elements of the RET region. The hundred highest scored 
alignments were mapped in the RET region. No overlap between the variants and the predicted 
enhancer elements was found. The highest scored element (score 258.42) was a 295 bp long fragment 
beginning 5624 bp upstream of RET and comprising nine putative transcription factor binding sites 
(Figure 8). We also screened a previously described non-coding RET variant (rs2435357 C>T) 
associated with the risk of Hirschsprung’s disease and situated within a conserved enhancer-like 
sequence in RET intron 1. The disease-associated allele is T and the wild-type allele is C (Emison et 
al. 2005). The T/T genotype was detected in three samples, T/C alleles were present in three samples 
and C/C in ten samples. Near this variant, EEL predicted a putative enhancer element (score 184.23) 
of 152 bp and comprising five transcription factor binding sites. The element begins IVS1+9343, 
which is 66 bp downstream of rs2435357 (IVS1+9277) (Figure 8).  
 
 
Figure 8. Results of EEL analysis. (A) Schematic illustration of RET gene with exons as gray boxes 
and putative enhancer elements as black boxes numbered according to best scores. (B) RET IVS1 
sequence with rs2435357 (bold, underlined) and the sixth element (underlined) with putative 
transcription factor binding sites (boxes).(C) Details of the six highest scoring elements predicted by 
EEL. 
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5.3 RET immunohistochemistry 
RET expression was positive (+) in 9/10 (90.0%) AIPmut- somatotropinomas. One AIPmut- 
somatotropinoma stained partly negative and partly positive (+/-). AIPmut+ somatotropinoma results 
were as follows: negative (-) in 3/7 (42.9%) samples, (+/-) in 2/7 (28.6%) samples and (+) in 2/7 
(28.6%) samples. When considering (-) staining vs. (+) and (+/-) staining with Fisher’s exact test, the 
two-sided p-value was 0.05. 
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Discussion 
1. Large genomic AIP deletions account for a subset of AIP mutations (I) 
The development of the MLPA technique has emerged as a methodological advance for identification 
of large genomic rearrangements (Schouten et al. 2002, Taylor et al. 2003). Recent studies have 
identified large genomic deletions in genes underlying familial pituitary adenoma, such as MEN1 and 
PRKAR1A (Kikuchi et al. 2004, Fukuuchi et al. 2006, Horvath et al. 2008). However, the possibility 
of such deletions in AIP has remained unsolved. Previously, an MLPA assay with custom-made 
probes for AIP and MEN1 was applied on pituitary tumor samples (Barlier et al. 2007). In one out of 
41 tumors, a germline R22X mutation was found in one AIP allele, and the other allele showed AIP 
LOH. A tumor sample from another patient had LOH of both AIP and MEN1, but no AIP or MEN1 
mutations were found in the other allele (Barlier et al. 2007). Thus, no germline AIP deletions have 
been found so far. In this study, for the first time, two out of 21 families were found to harbor large 
germline AIP deletions (Table 5, Figure 5).  
The AIP Ex2del (1562 bp) was identified in a family with NFPAs and GH-secreting adenomas from 
the UK, resulting in an in-frame ablation of 60 amino acids (A34_K93del) of AIP. It is likely that this 
large deletion (60/330 aa) leads to aberrant AIP protein function. The second AIP deletion, Ex1_2del 
(5818 bp), encompasses the 5’ end of AIP. It was found in previously reported German family with 
two acromegaly patients (Ackermann et al. 1999, Vierimaa et al. 2006). As Ex1_2del comprises a 
deletion of the whole 5’ end of the gene, it is predicted to be functionally equivalent to a whole gene 
deletion since the translation initiation codon and most likely part of the promoter region are lost. 
Alu elements are retrotransposons of the genome that are capable of generating genomic 
rearrangements such as deletions through e.g. the ectopic recombination between non-allelic 
homologous Alu elements (Cordaux & Batzer 2009). Partial and whole-gene deletions have 
previously been explained by the occurrence of Alu-mediated recombination events, for instance in 
LKB1, BRCA1, MLH1, MSH2, BRCA1 and MEN1 tumor suppressor genes (Nystrom-Lahti et al. 1995, 
Mauillon et al. 1996, Petrij-Bosch et al. 1997, Puget et al. 1997, Kikuchi et al. 2004, Fukuuchi et al. 
2006, Volikos et al. 2006). We examined whether the identified AIP deletions could be explained by a 
similar mechanism. An in silico search revealed the presence of eight Alu repetitive elements; four 
were located upstream of the 5’UTR and four spanned exon 2 (Figure 5). Indeed, an Alu-mediated 
recombination event may be likely for Ex2del since the deletion breakpoints are flanked by two 
reversely oriented Alu elements that have 89% sequence identity. This event would result in the 
retention of the IVS1 Alu repeat in the mutant allele, whereas most of the IVS2 Alu would be lost 
(Figure 5). The deletion breakpoints of Ex1_2del did not occur within Alu repeats, but in close 
proximity, so we hypothesize that this deletion might also occur due to Alu-mediated recombination 
between the Alu repeats upstream of the 5’UTR and the repeats in IVS2 (Figure 5).  
No copy number changes were detected among 35 sporadic Italian pediatric pituitary adenoma 
patients or 32 sporadic Finnish GH-secreting adenoma cases, although the patient series had been 
enriched for young cases, diagnosed at 40 years of age or less. According to previous reports, small 
intragenic germline AIP mutations are rare in sporadic pituitary adenoma patients (Barlier et al. 2007, 
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Cazabat et al. 2007, Georgitsi et al. 2007a). The present study suggests that the same could to be true 
for large genomic germline AIP alterations.   
The MLPA technique has certain disadvantages. For example, it merely allows the determination of 
relative copy number changes without identifying, for example, deletion breakpoints (Taylor et al. 
2003). Moreover, deletions may even remain undetected if their breakpoints occur outside a probe’s 
hybridization sequence (Knappskog et al. 2006). False negative results may also be due to 
contaminations, to which the MLPA assay is sensitive. It has also been reported that sequence 
variations at the binding sites of probes may prevent probe hybridization, leading to false positive 
results for deletions (MRC-Holland). In our set of samples, false positive results are highly unlikely 
since direct AIP sequencing covering the hybridization sites had been performed previously and the 
exact deletion breakpoints were successfully characterized by long range PCR. In conclusion, positive 
MLPA findings should optimally be further validated by sequencing on genomic DNA or cDNA 
level. 
This study shows, for the first time, that large genomic deletions in AIP underlie  a  subset  of  PAP.  
Special techniques such as MLPA, although not simple to perform, give the possibility to thoroughly 
screen for large alterations in AIP. We conclude that MLPA could be applied in PAP-suspected young 
patients with GH-secreting adenomas undergoing AIP genetic testing if conventional sequencing 
detects no AIP mutation. 
2. ARNT is underexpressed in AIP mutation positive pituitary adenomas (II) 
Although it is generally acknowledged that germline AIP mutations cause PAP, little is known about 
the exact molecular mechanisms leading to tumorigenesis (Vierimaa et al. 2006).  AIP  has  multiple  
cellular interaction partners and, thus, AIP mutations have the potential to interfere with a large array 
of cellular and environmental signals (Table 4). In this study, IHC of AIP-related molecules was 
applied to compare their expression in AIPmut+ and AIPmut- pituitary adenomas (Table 5). The 
xenobiotic response pathway involving AIP, AHR, ARNT and a DRE target gene CDKN1B1 (p27Kip1) 
was studied (Hankinson 1995, Carver & Bradfield 1997, Kolluri et al. 1999, Figure 3, see Review of 
the Literature 5.2.1). Also the hypoxia pathway, including the ARNT-HIF1-? complex function, was 
evaluated with HIF1-? and CD34 IHC (Gu et al. 2000, Figure 3, see Review of the Literature 5.2.1). 
Our main finding was the reduced expression of ARNT in AIPmut+ pituitary adenomas compared to 
AIPmut- samples (p=0.001, Table 6). Also a trend for increased nuclear expression of AHR in 
AIPmut+ adenomas was perceived, although the finding was not statistically significant (p=0.06). In a 
study by Jaffrain-Rea et al., no nuclear immunostaining of AHR was detected in AIPmut+ adenomas 
(Jaffrain-Rea et  al. 2009). Such a discrepancy might arise from differences in the IHC protocol or 
between the types of mutations studied. In contrast, another study by Nakata et al. observed weak 
nuclear accumulation of AHR after Aip siRNA treatment  in  an  Arnt-deficient mouse hepatoma cell 
line, supporting our observation (Nakata et al. 2009). 
Although AHR and ARNT expression was altered between AIPmut+ and AIPmut- adenomas, the 
expression of the target gene p27Kip1 was uniform between the two groups of tumors. In fact, all seven 
successfully stained AIPmut+ tumors showed prominent p27Kip1staining (intensity score 3). In the 
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AIPmut- tumors, there was more variation in intensities (scores 0 to 3). Similarly, in previous reports, 
p27Kip1 has been underexpressed or even lost in human pituitary tumors (Lidhar et al. 1999). 
However, additional AIPmut+ adenomas would be needed to ascertain the role of p27Kip1 in  AIP-
mediated tumorigenesis. 
Hypoxia affects the expression of oxygen-responsive genes, leading to upregulation of angiogenic 
factors and downregulation of inhibitors of angiogenesis (Ameln et al. 2005, Yoshida & Teramoto 
2007). Hypoxia in tumors leads, for example, to hypoxia-induced hematopoiesis and subsequent 
increases in the oxygen supply of the neoplasm (Hao et al. 2004). This process involves e.g. the 
stabilization of HIF1-?, which correlates with the expression of the endothelial marker CD34 (Wei et 
al. 2006). Previously, HIF1-? has been reported to be present in all types of pituitary adenomas (Vidal 
et al. 2003). Indeed, it is suggested that the exposure of pituitary adenoma cells to hypoxia may be a 
major driving force favoring tumor progression (Yoshida & Teramoto 2007). In this study, the 
expression of HIF1-? was found to be similar between AIPmut+ and AIPmut- adenomas. Moreover, 
we applied IHC of CD34 to detect possible changes in vasculature resulting from HIF1-?-ARNT 
complex imbalances and for cues of possible differences in the hypoxia responses of AIPmut+ and 
AIPmut- pituitary adenomas. The expression and density of CD34-positive vessels was found to be 
high and uniform in both tumor types (p=0.11). However, the standard deviation of CD34-vessels was 
high (319.5/mm2 ± 140.0 in AIPmut+ samples and 253.1/ mm2 ± 120.8 in AIPmut- samples). This was 
due to the small size of the adenoma pieces, which made the analysis technically challenging. 
Nevertheless, the high vessel density detected in AIPmut+ tumors with underexpression of ARNT 
suggests that the hypoxia response is functional despite the lack of ARNT. Obtaining of tumor 
material is the limiting factor in studies of AIPmut+ adenomas. Future research with a larger set of 
tumors would be desirable to assess possible differences in the hypoxia responses of AIPmut+ and 
AIPmut- adenomas.  
2.1 Implications of ARNT in other cellular pathways 
It has been reported that only 15% of the ARNT pool is sequestered by HIF1-? when the pathway is 
saturated and that induction of expression of certain HIF1-? target genes requires only small amounts 
of HIF1-?-ARNT (Pollenz et al. 1999, Tomita et  al. 2000). Thus, it is possible that when ARNT 
expression is not totally abolished, a required amount of ARNT exists to induce the expression of 
hypoxia-regulated genes. On the other hand, the ARNT homolog ARNT2 has been shown to be able 
to compensate for the lack of ARNT through binding with HIF1-? in response to hypoxia (Keith et al. 
2001, Sekine et al. 2006, Figure 3, see section 3.1). 
ARNT is a constitutively stable protein and it is ubiquitously present in nearly all cell types (Aitola & 
Pelto-Huikko 2003). Interestingly, ARNT has been implicated in diseases such as diabetes, breast 
cancer and lung cancer (Gunton et al. 2005, Kang et al. 2006, Weir et al. 2007). Also an ETS variant 
gene 6 (ETV)-ARNT fusion gene has been reported in T-lymphoblastic and acute myeloblastic 
leukemias (Salomon-Nguyen et al. 2000, Otsubo et al. 2010). These remarks support our assumption 
that ARNT may also have a role in pituitary pathogenesis.  
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The downregulation of ARNT in AIPmut+ tumors could be connected to an imbalance in the 
AHR/ARNT complex formation arising from aberrant cAMP signaling, which is often detected in 
pituitary tumors (Boikos & Stratakis 2007b). It was recently introduced that PDE2A is targeted by 
AIP  to  the  cytoplasmic  AHR complex  (de  Oliveira et al. 2007). Consequently, PDE2A inhibits the 
nuclear translocation of AHR by lowering the local cAMP levels (de Oliveira et al. 2007). Hence, it is 
conceivable that the lack of functional AIP in AIPmut+ tumors could result in the nuclear abundance 
of AHR in the presence of elevated cAMP levels. It has also been shown that cAMP-mediated AHR is 
able to adopt a unique structure and prevent the formation of the AHR-ARNT complex in the nucleus 
(Oesch-Bartlomowicz et al. 2005). Disturbances in AHR-ARNT and possibly HIF1-?-ARNT 
complexes may unbalance the transcription of specific target genes leading to pituitary tumorigenesis 
in AIPmut+ individuals. 
2.2 ARNT underexpression requires a pituitary tumor environment 
Our Aip siRNA assay showed partial reduction of ARNT in the GH3 mammosomatotroph cell line, 
but not in the non-pituitary cell lines (Aip-null and WT MEFs or AIP siRNA-treated HEK293 or HeLa 
cells) studied. Reduction of ARNT was detected already six hours after the electroporation-based Aip 
siRNA silencing. However, ARNT protein levels were restored 48 hours after the knockdown of Aip. 
These results suggest that ARNT might have a tissue-specific role in AIP-related tumorigenesis of the 
pituitary. GH3 was also the only cell line where we were able to show that knockdown of Aip leads to 
a clear increase in the cell proliferation rate, supporting the tumor suppressor role of AIP (Figure 6). 
This finding is in line with previous work by Leontiou et al., who noticed that overexpression of 
wildtype AIP in HEK293, GH3 and human diploid embryonic lung fibroblast TIG3 cells led to a 
reduction in cell proliferation (Leontiou et al. 2008). 
3. Aip heterozygous mice are extremely prone to pituitary adenomas (III) 
Recently, Lin et al. published the first Aip mouse model, in which homozygous germline mutations in 
Aip were embryonic lethal. However, the possible tumor formation in these mice was not reported 
(Lin et al. 2007, Lin et al. 2008). Thus, we decided to generate an Aip mouse to study for  the first  
time the tumor spectrum of  Aip HET mice and to model the PAP phenotype. We were successfully 
able to show that Aip HET mice had a substantially increased incidence of pituitary adenomas. First 
tumors in Aip HET  mice  were  detected  as  early  as  six  months  of  age  (Figure  7).  No  tumors  were  
detected at three months. This could be explained by the true rarity of pituitary adenomas in this age 
group or possibly by the lesions being too small to be detected with routine stainings. No excess of 
any other tumor types than pituitary adenomas were detected when comparing Aip WT  and  HET  
mice. GH-secreting adenomas dominated in the Aip HET group, although prolactinomas, two mixed 
GH+PRL, and one ACTH-secreting adenoma were also seen. Compared to human AIP mutation 
carriers, mixed GH/PRL adenomas were proportionally a less frequent tumor type in the Aip mouse. It 
has been estimated that the percentage of mammosomatotrophs is relatively high in the human 
pituitary (~25-50%) (Lloyd et al. 1988). In mice, however, the proportion of these cells has been 
reported to be much smaller (less than 20%) (Seuntjens et al. 2002). This difference between species 
may explain the relatively low frequency of mixed adenomas in Aip HET mice. All in all, the Aip 
mouse is extremely prone to pituitary adenomas also when comparing it with other mouse models 
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available (Williams et al. 1994, Nakayama et al. 1996, Franklin et al. 1998, Asa 2001, Crabtree et al. 
2001, Yin et al. 2008, Table 7). 
Overall, the Aip mouse model greatly resembles human PAP with a close to identical tumor 
phenotype with predominance of somatotropinomas. This suggests that the factors underlying 
Aip/AIP-deficient tumorigenesis are similar in both species (Vierimaa et al. 2006, Daly et al. 2007b, 
Georgitsi et al. 2007a, Leontiou et al. 2008). Full penetrance of pituitary tumors in Aip HET mice was 
reached at 15 months, emphasizing the fundamental importance of AIP for tumorigenesis in this 
organ. However, the penetrance of pituitary adenomas in PAP patients is distinctly lower than in Aip 
HET  mice  (15-45%  vs.  full  penetrance,  see  section  4).  This  could  be  due  to  species-specific  
differences in the susceptibility to pituitary adenomas, although the overall prevalence of pituitary 
adenomas has been estimated to be quite similar between mice and humans. Indeed, 21% of Aip WT 
mice developed pituitary adenomas, while the overall prevalence of these lesions in humans is 
estimated to be 17% (14% in autopsy studies and 23% in radiographic studies) (Ezzat et al. 2004). 
Another explanation in the difference of penetrances could be the difficulty in comparing the lifespan 
of mice and humans.  
As noted above, mouse models have been widely used to study pituitary development, function and 
disease, and recently Lin et al. published an Aip mouse model revealing that homozygous germline 
mutations in Aip are embryonic lethal and that these embryos die in utero due to cardiovascular 
malformations. Moreover, most mice with reduced Aip expression showed a patent ductus venosus 
resulting in reduced liver size. However, the possible tumor formation of these mice was not reported 
(Lin et al. 2007, Lin et al. 2008). In our study, Aip HET mice had the same or even slightly increased 
relative liver weights compared with their WT littermates. This discrepancy between the studies could 
be explained by differences in the strategy of generation or location of the germline Aip mutation, or 
possibly by the different C57BL substrains used for inbreeding (Strachan & Read 2004 p.605, Lin et 
al. 2007, Lin et al. 2008). In our study, crossings of Aip HET mice yielded one live Aip-null, 37 Aip 
HET  and  22 Aip WT embryos when analyzed at E12.5 stage. This deviates significantly from the 
expected Mendelian ratio (p<0.001). No living Aip-null mice were born. These results are in 
accordance with the previous study, where half of the Aip-null embryos died before E10.5 and none of 
the remaining fetuses survived past E14.5 (Lin et al. 2007). 
Acromegaly, which results from excessive GH secretion, is known to cause overgrowth of bones, 
joints and soft tissues in humans (Heaney & Melmed 2004). GH regulates the expression of Igf-1 in 
the liver and causes elevated systemic IGF-I levels that mediate the effects of the secreted GH 
(Ohlsson et al. 2009, Sane in Välimäki et al. 2009 p.82-84). It was shown that the expression of Igf-1 
in the liver of somatotropinoma-bearing Aip HET mice was higher than in control animals, clearly 
indicating that the GH secreted by Aip-deficient somatotropinomas is functional. We also detected 
signs of increased relative organ weights in Aip HET mice (?15 months), although these weight 
differences were not statistically significant. However, the lack of significance may be due to the 
relatively small number of mice in each group. 
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Table 7. Mouse models that are prone to pituitary adenomas. 
Defective gene Pituitary adenomas and other phenotypic effects in mice Reference 
Men1 26% PRL-secreting adenomas (heterozygous mice), tumors Crabtree et al. 2001 
 
of the pancreas, parathyroid, thyroid and adrenal cortex 
 Prkar1a 48% different pituitary tumor types (tissue-specific  Yin et al. 2008  
 
knockout mice), no other phenotypic effects 
 p27(Kip1) ~50% intermediate lobe pituitary tumors (knockout mice), Nakayama et al. 1996 
 
e.g. enlarged size, female sterility, retinal dysplasia 
 Rb Full penetrance of intermediate lobe pituitary tumors  Williams et al. 1994 
 
(knockout chimeras), e.g. cataracts, hyperplasia 
 
 
of the adrenal medulla, enlarged cells in liver 
 p18(Ink4) Nearly full penetrance of intermediate lobe pituitary tumors   Franklin et al. 1998 
  (knockout mice), e.g. increased size, hyperplasia of the spleen   
 
 
3.1 Aberrant ARNT/ARNT2 expression in Aip-deficient pituitary adenomas 
IHC of ARNT and ARNT2 revealed the total lack of either protein in Aip-deficient mouse pituitary 
tumors compared with Aip-proficient tumors. This finding parallels our earlier work where ARNT 
protein was significantly reduced in human AIPmut+ pituitary tumors (see study II). Strikingly, we 
found  out  that  nearly  always  there  was  loss  of  either  ARNT  or  ARNT2,  in  a  mutually  exclusive  
manner, in Aip-deficient tumors (p<0.00001, Table 6). The presence of HIF1-? indicated the 
activation of the hypoxia response both in Aip-deficient and -proficient adenomas. The level of HIF1-
? was  higher  in  Aip-proficient prolactinomas than in Aip-deficient somatotropinomas, and it has 
accordingly been reported in humans that prolactinomas have a tendency to show a higher HIF1-? 
protein expression level than GH-secreting adenomas (Yoshida et al. 2005). In addition, all five 
stained Aip-deficient prolactinomas showed strong HIF1-? staining.  
Tumors often constitute a hypoxic environment, reflecting their increased demand for oxygen. 
Although hypoxia is toxic to cells, cancer cells may undergo genetic and adaptive changes allowing 
their survival and proliferation. Under hypoxia, ARNT can heterodimerize with HIF1-? to generate an 
active complex HIF1 that regulates the expression of target genes. Thus, ARNT has an essential part 
in the response to hypoxia. HIF1-? has been shown to contribute to proliferation, angiogenesis, 
metastasis and resistance to radiation therapy of tumors (Graeber et al. 1996, Gu et al. 2000, Harris 
2002, Rankin & Giaccia 2008, Figure 3). ARNT2 is a homolog of ARNT that was initially discovered 
to be expressed in neural tissue and the kidney (Hirose et al. 1996). In this study, we showed that 
ARNT2 is also expressed in the pituitary. While much is known about the function of ARNT, the 
dimerization partners and roles of ARNT2 are less clear. Interestingly, ARNT2 has been shown to be 
able to compensate for the lack of ARNT through binding with HIF1-?, but seemingly has a limited 
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ability to influence AHR-mediated signaling (Hirose et al. 1996, Maltepe et al. 2000, Sekine et al. 
2006, Dougherty & Pollenz 2008, Figure 3). However, other studies have suggested that AHR and 
ARNT2 are dimerization partners (Kretzschmar et al. 2010, Lee et al. 2011, Figure 3). ARNT 
proteins and AIP are not known to be direct interaction partners, and the connection between both 
ARNT proteins and AIP is through AHR (Figure 3). However, the effect of this connection is 
currently unclear both in physiology and tumorigenesis, and the roles of these proteins have not been 
thoroughly defined in previous studies. Overall, while the mechanism behind the lack of ARNT or 
ARNT2 observed in Aip-deficient pituitary adenomas remains to be elucidated, it can be suggested 
that signaling through these proteins is a key factor in pituitary tumorigenesis after loss of AIP 
function. 
Interestingly, previous knockout mice models of Aip, Arnt, Arnt2, Hif1-? and Ahr show signs of e.g. 
vascular and pituitary abnormalities (Fernandez-Salguero et al. 1995, Maltepe et al. 1997, Kotch et al. 
1999, Hosoya et al. 2001, Lin et al. 2007, Table 8). However, not much is currently known about the 
expression of hypoxia target genes in pituitary adenomas. It has been suggested that the expression of, 
for example, the hypoxia target gene vascular endothelial growth factor (VEGF) would not be an 
important vasculogenic pathway in pituitary adenomas under hypoxia (Kim et al. 2005). It has also 
been reported that glucose transporter 1 (GLUT1), another hypoxia responsive gene, is under the 
regulation of GH (Tai et al. 1990). Therefore, the expression of these genes would not necessarily 
correlate exclusively with the hypoxia in pituitary adenomas, and that is why the expression of 
hypoxia responsive genes was not studied in this work.   
Table 8. Phenotypes of homozygous knockout mouse models of genes encoding AIP-related proteins. 
Defective gene Phenotype Reference 
Aip Embryonic lethality: decreased blood flow to head and limbs,  Lin et al. 2007 
 
heart deformations 
 Arnt Embryonic lethality: defective angiogenesis of the yolk sac  Maltepe et al. 1997 
 
and compromised capillary development in solid tissues 
 Arnt2 Death shortly after birth: defective development of   Hosoya et al. 2001 
 
hypothalamic secretory neurons, hypoplastic posterior pituitary 
 Hif1-? Embryonic lethality: cardiac and vascular abnormalities Kotch et al. 1998 
Ahr Half die shortly after birth: immune system impairment,  Fernandez-Salguero 
  liver size reduction  et al. 1995 
 
3.2 Other characteristics of Aip-deficient and -proficient pituitary adenomas 
The ER signaling pathway acts in the biosynthesis and secretion of hormones of the anterior pituitary 
and stimulates the proliferation of lactotrophs and gonadotrophs (Pereira-Lima et al. 2004). ARNT 
and ARNT2 both have a potent role in the regulation of ER signaling (Brunnberg et al. 2003, 
Matthews & Gustafsson 2006, Swedenborg & Pongratz 2010, Figure 3). The AHR-ARNT complex 
can, for example, directly bind inhibitory xenobiotic response elements (iXREs) regulating ER target 
gene expression, cause increased proteasomal degradation of ER, or alter estrogen synthesis or 
metabolism through increases in aromatase, CYP1A1 and CYP1B1 expression (Brunnberg et  al. 
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2003, Matthews & Gustafsson 2006). We detected uniform expression of ER? between Aip-deficient 
and -proficient prolactinomas. In contrast, Aip-deficient GH-secreting adenomas had lower ER? 
expression compared to Aip-deficient and -proficient prolactinomas. This is in accord with earlier 
studies that report that prolactinomas have a tendency to show higher ER? levels than GH-secreting 
adenomas (Nakao et al. 1989, Zafar et al. 1995). Although we were not able to compare ER? 
expression between Aip-deficient and -proficient GH-secreting adenomas due to their rarity in Aip 
WT  mice,  our  results  rather  suggest  that  ER? would  not  be  a  key  factor  in  AIP-related  pituitary  
tumorigenesis. Estrogen receptor ? (ER?) expression was not evaluated in this work because of the 
lack of functional ER? antibodies. 
IHC analysis of the proliferation marker Ki-67 showed that Aip HET pituitary tumors had higher 
proliferation rates than Aip WT adenomas (p=0.014). The average proliferation index of 3.6% 
detected in tumors of Aip WT mice is comparable with values detected in human sporadic pituitary 
tumors (1-4%) (Knosp et al. 1989, Mastronardi et  al. 1999, Jaffrain-Rea et al. 2002). In humans, 
AIPmut+ tumors have been reported, for example, to be larger and to have a poorer response to SSA 
therapy (Daly et al. 2007b, Leontiou et al. 2008, see study IV). Also our result suggests that AIPmut+ 
adenomas may have more aggressive characteristics than their sporadic counterparts. 
This study reveals for the first time that Aip HET mice display a disease phenotype that is strikingly 
similar to PAP patients. Importantly, the phenotype conferred by human and mouse AIP/Aip germline 
mutations appears to contain only pituitary adenomas, with GH-secreting adenomas accounting for 
78% and 88%, respectively (see study IV). This dramatically increased risk of somatotropinomas 
makes AIP an attractive candidate gatekeeper gene of somatotrophs, an issue that requires further 
studies for verification. All in all, the generation of this mouse model provides an ideal tool to further 
elucidate the molecular basis of pituitary tumorigenesis, for example the hypoxia and estrogen 
responses and cAMP signaling in AIP/Aip-deficient adenomas. It may also have potential in efforts to 
develop therapeutic strategies in the management of difficult-to-treat pituitary adenomas.  
4. AIP mutation positive patients display an aggressive disease phenotype (IV) 
This study reports the clinical features and therapeutic responses of 96 AIPmut+ patients, compared 
with a control population of 232 AIPmut- acromegalics (Vierimaa et al. 2006, Barlier et al. 2007, 
Daly et al. 2007b, Georgitsi et al. 2007a, Naves et al. 2007, Toledo et al. 2007, Georgitsi et al. 2008, 
Jaffrain-Rea et al. 2009, Jennings et al. 2009, Table 5). Nearly 80% of AIPmut+ patients presented 
with somatotropinomas, and more than half co-secreted GH and PRL. Every third AIPmut+ 
somatotropinoma patient had gigantism. Prolactinomas were present in 13.5% of patients, and also 
NFPA was a clear feature of the tumor spectrum of PAP. This study also included the first reported 
AIPmut+ TSH-secreting  adenoma.  As  TSH-secreting  tumors  are  rare,  it  remains  to  be  seen  if  AIP 
mutations could be frequent in this setting (Beck-Peccoz et al. 1996, Arafah & Nasrallah 2001). 
Cushing’s disease seems to be very rare in AIPmut+ patients with only two cases described in the 
literature and none in the current series (Georgitsi et al. 2007a, Stratakis et al. 2010). This was the 
first international and multicenter retrospective case collection/database analysis of the characteristics 
of AIPmut+ patients. 
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The reason for predominance of somatotropinomas among AIPmut+ patients is still unclear. However, 
these patients had specific features compared to an AIPmut- control somatotropinoma group. 
AIPmut+ somatotropinoma patients were diagnosed with pituitary adenomas two decades earlier than 
control patients. Their adenomas were larger, with more frequent extrasellar extension and PRL 
hypersecretion. In addition, the AIPmut+ somatotropinomas were associated with higher levels of GH 
secretion at baseline versus controls. These features appeared to impact therapeutic responses, with 
poorer disease outcomes seen in the AIPmut+ group. Large, invasive and extensive macroadenomas 
and high GH secretion were associated with a lower rate of disease control with primary 
neurosurgery, leading to higher rates of re-operation in the AIPmut+ cohort (Buchfelder & Schlaffer 
2009). A trend towards more frequent radiotherapy and failure of pegvisomant to control IGF-I was 
seen in AIPmut+ individuals compared with control patients. In addition, SSA therapy led to a smaller 
decrease in GH and IGF-I baseline and less tumor shrinkage in the AIPmut+ group than in controls. 
The  reason  for  poorer  responses  to  SSAs  is  not  known  and  this  would  be  an  interesting  issue  for  
further study, particularly since somatostatin receptor expression and the activity of vital determinants 
of SSA function such as ZAC1 in AIPmut+ somatotropinoma cells remain unknown (Theodoropoulou 
et al. 2009). Large tumor size and a poor SSA response in such cases might require tumor debulking 
to favor eventual control with SSA (Petrossians et al. 2005, Karavitaki et al. 2008).  
Gigantism is a rare manifestation of GH oversecretion, with a little more than 100 cases reported so 
far in the literature (Eugster & Pescovitz 1999, Schoof et al. 2004, Rix et al. 2005, Müssig et al. 2007, 
Goldenberg et al. 2008). In exceptional cases, gigantism may occur in MEN1, CNC, or MAS (Eugster 
& Pescovitz 1999). In contrast, 32% of AIPmut+ somatotropinoma patients displayed gigantism 
compared to 6.5% of controls, suggesting that gigantism may be a frequent finding among AIPmut+ 
patients and perhaps not as rare as previously thought in AIPmut- patients either. Gigantism occurred 
in a familial setting in 63% of AIPmut+ cases; additionally there were nine giants with no family 
history of pituitary adenomas. In contrast, Leontiou et al. found no AIP mutations among seven 
sporadic giants, although gigantism appeared to occur frequently among their FIPA kindreds 
(Leontiou et al. 2008). The frequent gigantism in AIPmut+ patients most likely results from large 
somatotropinomas secreting high levels of GH that become symptomatic before epiphyse closure in 
young patients.  
In the AIPmut+ group, there was an unequal representation of males and females, with about two-
thirds of patients being male. In contrast, there is generally a female preponderance of pituitary 
adenomas, with a female:male ratio ranging from 1.23 to 2.05 (Thapar et al. 2001 p.61). In study III, 
we did not detect differences between sexes in the pituitary adenoma formation of Aip HET mice. The 
sex imbalance of PAP patients was especially remarkable in the AIPmut+ prolactinoma group, which 
was 76.9% male. These patients had large tumors that were often uncontrolled by dopamine agonists, 
multiple surgery and radiotherapy. The male sex is generally known to be associated with a higher 
rate of aggressive or treatment-resistant prolactinomas, and possible underlying AIP mutations could 
explain part of those cases (Ciccarelli et al. 2005, Colao 2009). Overall, the male preponderance seen 
in this study differs markedly from the pituitary disease characteristics in MEN1, where 69% of 
patients  are  female.  This  difference  may  be  due  to  the  fact  that  prolactinomas  comprise  62%  of  
pituitary tumors in MEN1 and are more frequent in women (Verges et al. 2002). Due to the 
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differences in symptomatology, women usually present earlier than men (Ciccarelli et al. 2005). 
Interestingly, prolactinomas in MEN1 patients are relatively difficult to treat, similar to AIPmut+ 
cases. CNC is also a disease with a strong female preponderance (63%). While acromegaly is a 
recognized phenotypic component of CNC, it is relatively uncommon, making valid comparisons with 
AIPmut+ patients difficult (Bertherat et al. 2009). 
The penetrance of PAP remains an unsolved question. Based on the current figures (over 100 
asymptomatic AIPmut+ carriers related to patients in this study), the penetrance of pituitary adenomas 
among FIPA kindreds with AIP mutations is 15-45%. Although most (nearly 90%) AIP mutation-
related adenomas present before the age of 40, many younger AIP mutation carriers will need 
extended follow-up in order to definitively determine the penetrance. Current penetrance 
determination suffers from various sources of bias, such as small families, limited possibilities for 
clinical and genetic assessment, inadequate follow-up time of families, as well as seemingly sporadic 
patients where AIP genetic testing in the family is not possible. In contrast, Aip HET mice displayed 
pituitary adenomas starting from six months (6/18 mice; 33%) reaching complete penetrance at 15 
months. At six months, no pituitary adenomas were seen in Aip WT mice (0/10 mice; 0%). However, 
we would have required larger groups of young HET mice to determine whether the penetrance of 
these young mice could be similar to that of young PAP patients. 
As demonstrated by large families, for example in Finland and Italy, founder mutations of AIP seem 
to exist (Vierimaa et al. 2006, Naves et al. 2007, Jennings et al. 2009, Occhi et al. 2010). This 
suggests that the AIP mutation status does not greatly impair biological fitness, unlike in some 
aggressive genetic tumor syndromes (Wang et al. 1999). It remains to be determined whether some 
specific AIP mutations could confer a lower disease penetrance than others. The fact that more than 
half of AIPmut+ patients present with extensive pituitary macroadenomas as children or adolescents 
suggest that the AIP germline mutation confers a predisposition to rapid tumor growth, evidenced by 
the short time (2.0 yr) from first symptoms to diagnosis.  
The tumorigenesis caused by the known human AIP mutations has not been thoroughly studied yet. It 
can, however, be perceived that AIP nonsense mutations are spread along the gene. Instead, AIP 
missense mutations mostly tend to cluster in the carboxy-terminus of AIP. This region harbors the 
TPR domains that mediate protein-protein interactions of AIP, suggesting that missense mutations in 
this region could impair cellular interactions of AIP (Carver & Bradfield 1997, Petrulis & Perdew 
2002, Figure 2).  
The clinical characteristics of PAP have not yet been fully elucidated, which may impede the 
treatment of patients and the recognition of putative PAP families. We found AIP-related pituitary 
adenomas to be most often large, expansive and invasive at diagnosis. Patients are predominantly 
males. Half of cases present during childhood or adolescence, manifesting remarkably frequent 
gigantism. AIP-related pituitary adenomas appear also to have many aggressive and difficult-to-treat 
clinical characteristics. The aggressive nature of AIPmut+ adenomas is endorsed by the increased 
expression of the Ki-67 proliferation marker in Aip-deficient mouse pituitary adenomas (see study 
III). Interestingly, it was recently shown that low AIP expression is a better marker of invasiveness in 
sporadic somatotropinomas than Ki-67 and p53 (Kasuki Jomori de Pinho et al. 2010). These results 
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suggest that to improve outcomes of AIP-associated pituitary tumors, earlier diagnosis is required. 
Thus, it is important to explore the most appropriate ways to identify new PAP patients, allocating 
genetic screening especially for FIPA kindreds and young patients with large tumors (Beckers & Daly 
2007).  
5. No evidence of RET mutations in familial pituitary adenoma patients (V) 
The RET proto-oncogene (10q11) is a tyrosine kinase transmembrane receptor (Trupp et  al. 1996, 
Trupp et  al. 1998). Gain-of-function mutations of RET cause  MEN2A,  MEN2B  and  familial  
medullary thyroid carcinoma, while loss-of-function mutations of RET produce the 
neurodevelopmental disorder Hirschsprung’s disease (Mulligan et al. 1993, Romeo et al. 1994, Arighi 
et al. 2005). AIP was recently shown to interact in vivo in the pituitary with the RET proto-oncogene 
(Table 4). AIP interacts with the pro-apoptotic domain of RET, and clinically pathogenic RET or AIP 
mutations that were introduced to cell constructs did not impair the interaction. In the same study, no 
somatic RET mutations were found in the 28 screened somatotropinomas (Vargiolu et al. 2009). RET 
mutations have also previously been searched for in human pituitary adenomas but no relevant 
mutations have been found (Komminoth et al. 1996, Yoshimoto et al. 1999, Vieira Neto et al. 2007). 
However, previous studies have not assessed RET germline mutations in familial pituitary adenomas, 
and it is not known whether RET mutations could cause a rare familial pituitary adenoma phenotype, 
similar to AIP mutations. In AIPmut- familial pituitary adenoma patients, altogether five previously 
unreported RET variants were found, of which two segregated with the phenotype. In a British 
prolactinoma patient we found a heterozygous c.1560*G>A change in the 3’UTR, which was also 
present  in  the  affected  sister  but  absent  in  279  control  samples  and  an  unaffected  sister.  Also,  a  
heterozygous -1285G>A change was found in a Vietnamese patient and her affected child. However, 
this variant is quite far from the coding region of RET and is not located on any reported promoter or 
regulatory RET region (Guo et al. 2007). 
5.1 EEL results provide data on regulation of RET transcription 
The EEL tool has recently been applied in detection of enhancer elements of genes causing colorectal 
cancer predisposition (Tuupanen et al. 2009). In this study, EEL was applied to predict possible 
enhancer elements overlapping the two segregating RET changes, but no such elements were found. 
Thus,  it  seems  unlikely  that  these  variants  would  be  related  to  pituitary  tumorigenesis.  We  also  
analyzed the noncoding RET variant rs2435357 C>T within a conserved enhancer-like sequence, 
which is a low-penetrance risk allele for Hirschsprung’s disease. The disease-associated T allele 
reduces in vitro RET enhancer activity and decreases transcription (Emison et al. 2005). The risk 
allele was present in three samples in the homozygous form. Another three specimens were 
heterozygous, and the remaining ten were homozygous for the wildtype C allele. Patients harboring 
the T allele (n=6) had heterogenous demographics and tumor types. All in all, the allele frequencies 
we found are similar to previously described population frequencies of C and T alleles (Emison et al. 
2005). Thus, rs2435357 seems unlikely to have an impact on pituitary tumorigenesis. Previously, 
rs2435357 has been found to reside within a predicted serum response factor (SRF) binding site 
(Grice et al. 2005). Also, the enhancer-like sequence containing rs2435357 was demonstrated to 
function as a tissue-specific enhancer in vivo (Grice et al. 2005). EEL predicted an enhancer element 
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beginning 66 bp downstream of rs2435357, with the first putative transcription factor binding site 
beginning 75 bp downstream of it (Figure 8). Notably, four out of the six best scored elements that 
were predicted were located within previously reported multi-species conserved sequences (MSC) of 
human and zebrafish (Grice et al. 2005, Fisher et al. 2006). Finding overlapping sequence elements 
with different techniques increases their reliability. However, these four MCSs are much longer than 
the predicted EEL elements that they contain. It is plausible that increasing the amount of 
transcription factor binding matrices in EEL could enlarge the predicted element and increase the 
number of putative transcription factor binding sites (Emison et al. 2005, Grice et al. 2005, Fisher et 
al. 2006). Our predicted RET enhancer with the highest score was a 295 bp long element beginning 
5624 bp upstream of RET, comprising nine transcription factor binding sites (Figure 8). Grice et al. 
showed that MCS-5.2, a multi-species conserved sequence comprising our predicted enhancer, 
enhanced luciferase expression in neuronal cells (Grice et al. 2005). Located near the RET promoter 
area, this predicted element could have a role in the control of RET expression, although further 
functional and in vivo studies are needed to verify this. 
5.2 RET underexpression in AIP mutation positive somatotropinomas 
In the normal pituitary gland, RET is expressed in somatotrophs where it is associated with apoptosis 
and differentiation (Urbano et al. 2000, Japon et al. 2002, Canibano et al. 2007). In pituitary 
adenomas, RET has been shown to be present in somatotropinomas and in a subset of 
corticotropinomas (Japon et al. 2002). Our RET IHC results on AIPmut+ and AIPmut- 
somatotropinomas indicate possible RET underexpression in AIPmut+ somatotropinomas (p=0.05). 
This finding could suggest a putative role for RET in AIP-related pituitary tumorigenesis. It is 
possible that the loss of AIP protein in AIPmut+ adenomas would prevent the interaction between AIP 
and RET. By an unknown mechanism, this could lead to loss of RET in the tumor, causing inhibition 
of apoptosis and subsequent pituitary tumorigenesis (Canibano et al. 2007). Since RET is expressed 
exclusively in somatotrophs, it could be logically linked to the tumorigenesis of somatotropinomas, 
which are the most common phenotype of PAP patients. However, AIP mutations also predispose to 
other tumor types such as prolactinomas, and the correlation between RET and these tumors remains 
an open question. All in all, reduced RET expression may play a role in AIP-related genesis of 
somatotropinomas; it would be important to study the expression of RET in a larger set of 
somatotropinomas in the future, since this study only included a small number of samples.  
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Conclusions and Future Prospects 
This work aimed to clarify the molecular mechanisms and clinical characteristics of familial pituitary 
adenoma. The main conclusions drawn from this study are summarized as follows: 
I) Large genomic deletions were discovered as a new mutation type in AIP, underlying a subset of 
PAP cases. Therefore, AIP MLPA could be applied in suspected PAP patients undergoing AIP genetic 
testing if conventional genomic sequencing analysis of AIP remains mutation negative. 
II) Expression of ARNT was reduced in AIPmut+ pituitary adenomas compared with AIPmut- 
adenomas. This suggests that ARNT may play a role in AIP-mediated pituitary tumorigenesis, 
possibly via pathways that involve PDEs and cAMP.  
III) Aip HET mice  and  PAP  patients  displayed  a  strikingly  similar  disease  phenotype,  with  GH-
secreting adenomas accounting for 78% and 88% of pituitary tumors, respectively. The dramatically 
increased risk for somatotropinomas suggests that AIP is a candidate gatekeeper gene of 
somatotrophs. Supporting the finding of ARNT underexpression in AIPmut+ adenomas in study II, 
mutually exclusive ARNT or ARNT2 underexpression was evident in mouse Aip-deficient pituitary 
adenomas. This may indicate an ARNT/ARNT2 imbalance and an aberrant ARNT/ARNT2 function 
in AIP-related tumorigenesis. All in all, the generation of this mouse model provides an ideal tool to 
further elucidate the molecular basis of pituitary tumorigenesis. It may also have potential in efforts to 
develop therapeutic strategies in the management of difficult-to-treat pituitary adenomas. 
IV) AIPmut+ adenomas conferred an aggressive disease phenotype, with young age at disease onset 
and difficult-to-treat clinical characteristics. These results are supported by the aggressive nature of 
Aip-deficient mouse pituitary adenomas in study III. Improving the treatment outcomes of PAP 
patients would require their efficient identification, as well as earlier diagnosis of pituitary tumors.  
V) We found novel heterozygous RET variants in AIPmut- familial pituitary adenoma patients with an 
as yet unidentified mechanism underlying adenoma formation. However, none of these RET variants 
were considered causative of pituitary tumorigenesis. Interestingly, underexpression of RET protein in 
AIPmut+ pituitary adenomas was observed, although additional studies are necessary to verify this. 
Important questions remain to be answered regarding AIP-related pituitary tumorigenesis. It is 
postulated that tumors may arise from different ‘cells of origin’. The adult pituitary has been shown to 
contain stem cells, although whether pituitary pathogenesis could be related to trophic activity of 
these cells, and what role germline AIP mutations could have in this setting, is still unclear.  
In future studies, the molecular mechanisms and cellular pathways of AIP-related pituitary 
tumorigenesis should be elucidated. Whole-genome RNA-based expression profiles from Aip-null and 
WT MEF cell lines would be most desirable, to provide insight into the pathways in which AIP plays 
a crucial role.  
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In addition, it would be interesting to compare the RNA expression profiles of AIP-deficient and    
AIP-proficient pituitary adenomas. In humans, collecting such adenomas is time-consuming, since 
fresh tumor material from pituitary adenenomectomies of AIPmut+ patients is exceedingly rarely 
available.  However, the Aip mouse has the potential to provide large numbers of Aip-deficient and -
proficient tumors. This presents the possibility to study AIP-mediated tumorigenesis in the relevant 
tissue and in a microenvironment with the appropriate molecular background. 
AIP mutations confer an aggressive disease phenotype that causes both severe morbidity in PAP 
patients and concern for unaffected mutation carriers. To improve the long-term outcome for 
AIPmut+ patients, the PAP diagnosis should lead to possible tailored treatment, as well as to optimal 
follow-up of AIPmut+ patients and healthy mutation carriers. These are issues that should be 
addressed in future studies on PAP penetrance and the response of PAP patients to various treatment 
modalities.  
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